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1. INTRODUCTION 
 
1.1 Angiogenesis 
Angiogenesis, the formation of new blood vessels from preexisting ones (1), is involved in 
many physiological processes during reproduction, development and wound repair. 
However, it is also part of many pathophysiological processes, including ischemic, 
inflammatory, infectious and immune disorders (1, 2). Since the establishment of new blood 
vessels provides growing tumors with oxygen and nutrients (1), the induction of angiogenesis 
is regarded as one of the hallmarks of cancer (3).  
 
1.1.1 The process of angiogenesis 
Angiogenesis is a multi-step process, which is controlled by stimulators and inhibitors (4). 
Normally, vasculature is quiescent and only a small portion of endothelial cells is proliferating 
(5, 6). However, if the amount of pro-angiogenic factors such as vascular endothelial growth 
factor (VEGF) increases due to stimuli like hypoxia, endothelial cells undergo the “angiogenic 
switch” (7) and are activated (8) (Fig. 1/1). Tumors as well as activated endothelial cells 
secrete matrix-metalloproteinases (MMPs). The vascular basement membrane is degraded 
and endothelial cells migrate in order to form sprouts (Fig. 1/2). Integrins are upregulated 
facilitating endothelial cells to bind to extracellular membranes. Finally, new capillaries are 
formed out of proliferating endothelial cells as well as precursor bone-marrow-derived 
endothelial cells ((2), Fig. 1/3, Fig. 1/4).  
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Figure 1: Multi-step cascade of tumor angiogenesis. 
Stimuli like hypoxia induce the secretion of pro-angiogenic factors by tumors as well as endothelial 
cells (1). Thereby endothelial cells get activated, migrate (2) and proliferate to form new sprouts. 
Precursor bone-marrow-derived endothelial cells also contribute to the vessel formation (3). New 
sprouts supply the tumor with nutrients and oxygen (4). Abbreviations: PF, pro-angiogenic factors; 
EPC, endothelial progenitor cells. 
 
1.1.2 Inhibitors of angiogenesis in cancer therapy 
Since tumor progression and invasion as well as the formation of metastasis depends on its 
blood supply, inhibitors of angiogenesis have become of increasing interest in recent years 
(1). The most notable anti-angiogenic drugs currently used for cancer therapy such as the 
antibody bevacizumab (Avastin, Genentech/Roche) (1) and the multikinase inhibitors 
sorafenib (Nexavar, Bayer) and sunitinib (Sutent, Pfizer) target VEGF signaling (9). However, 
patients inescapably develop resistances including the upregulation of other growth factors 
and cytokines (10), as well as the induction of hypoxia inducible factors (HIFs) (11). So there 
is a great need for new therapeutic options which could target such evasive mechanisms, 
finally leading to a higher efficacy of anti-angiogenic therapy. 
  
1 hypoxia 2 hypoxia
3 hypoxia 4
PF
EPC
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1.2 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death in the 
world (12). It is highly prevalent in Asian countries due to widely distributed hepatitis B virus 
infections (13). However, there is also a growing incidence in Western countries, because of 
increasing rates of hepatitis C virus infections (14). The majority of HCC patients have an 
impaired liver function, up to 80% are suffering from cirrhosis (15). This leads to altered 
pharmacokinetics, making it very difficult to determine the right drug dose for treatment. 
Although some cytotoxic chemotherapeutics such as doxorubicin or cisplatin have shown 
antitumor activity in HCC patients, the survival benefit is very limited (9). To date, no 
satisfying systemic treatment against HCC exists. Even after surgical therapy there is a high 
rate of tumor recurrence (16).  
HCC is one of the most vascularized solid tumors (17) showing an increased VEGF 
expression (18) and a direct correlation of high VEGF levels with worse overall survival in 
patients (19). Furthermore, angiogenesis in HCC correlates with the risk of vascular invasion 
and metastasis (20, 21). Therefore, targeting tumor angiogenesis might be a useful tool for 
HCC treatment (22). First pre-clinical studies with anti-angiogenic agents had been very 
promising, but could not be confirmed in clinical trials (23). So far, the multikinase inhibitor 
sorafenib is the only approved systemic anti-angiogenic drug for advanced-stage HCC. 
However, the median survival of patients is just increased by 2.8 months in comparison to 
the control group (9). Thus, further targets have to be identified to improve anti-angiogenic 
therapy. 
 
1.3 Cyclin-dependent kinase 5 
Cyclin-dependent kinase 5 (CDK5) is a serine/threonine kinase which has been identified 
more than 20 years ago in bovine brain extract (24). It is unique among other CDKs because 
it is no classical mediator of cell-cycle transitions but is implicated in neuronal development, 
function and disease (25). In neuronal cells, its activity is mainly regulated by the association 
with the catalytic subunits p35 and p39. Interaction with their truncated forms p25 and p29 
results in deregulation, abnormal target phosphorylation as well as mis-localization. This 
contributes to the pathogenesis of several diseases, like neurodegeneration (25). 
Furthermore, the activity of CDK5 is regulated by phosphorylation at Tyr15 by the kinases 
c-Abelson (c-Abl) and Fyn (26, 27). Already a lot of knowledge is gained about CDK5 in 
neuronal cells. However, in recent years it has become increasingly clear that CDK5 also has 
1 INTRODUCTION 
14 
 
extra-neuronal functions e.g. in epithelial tissues, the immune system, cancer, metabolism 
and the endothelium (25). 
1.3.1 CDK5 in cancer 
Several studies indicate an involvement of CDK5 in different types of cancer. Feldmann et al. 
showed that CDK5 is broadly active in pancreatic cancer cells and that its inhibition reduced 
invasion, migration and anchorage-independent growth in vitro as well as orthotopic tumor 
formation and systemic metastases in vivo (28). Furthermore, Demelash et al. suggested a 
correlation between CDK5 activity and cell migration in lung carcinogenesis (29). CDK5 is 
also described to be involved in medullary thyroid carcinoma progression and tumorigenesis 
(30). Interestingly, CDK5 is highly expressed in hepatocellular carcinomas and an inhibition 
of the kinase has been shown to reduce HCC cell proliferation and clonogenic survival. 
Additionally, in vivo efficacy of CDK5 inhibition was demonstrated in HCC xenograft mouse 
models (Ehrlich et al., Journal of Hepatology, in revision).  
1.3.2 Role of CDK5 during angiogenesis 
Recent findings demonstrate that CDK5 is also a key regulator of angiogenesis (31). CDK5 
inhibition was shown to reduce endothelial cell motility in vitro and in vivo by decreasing the 
activity of the small GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1), leading to a 
disorganized actin cytoskeleton (31). Moreover, a role of CDK5 in endothelial cell growth has 
been demonstrated, as high levels of CDK5 are found in proliferating bovine aortic 
endothelial cells and CDK5 is upregulated by basic fibroblast growth factor. Additionally, 
endothelial cell proliferation has been described to be inhibited by down-regulation of CDK5 
(32) and CDK5 activity is shown to correlate with VEGF expression in pituitary adenomas 
(33). 
1.3.3 CDK5 inhibitors 
CDK5 has been identified to contribute to several pathological processes. Besides its 
involvement in neurodegenerative diseases such as Alzheimer´s (34-36) and Parkinson´s 
disease (37) as well as cancer, it is also connected to Huntington´s disease (38), stroke (39), 
pain signaling (40, 41) and pancreatic insulin secretion (42). Therefore, the development of 
inhibitors is of great interest. The earliest well-known inhibitors of CDKs are olomoucine (43) 
and roscovitine (Seliciclib CYC202) (44), which are 2,6,9-trisubstituted purines (45) (Fig. 2). 
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Figure 2: Chemical structure of olomoucine and (R)-roscovitine. 
 
However, they do not inhibit CDK5 specifically, since they generally interact with the ATP-
binding site of CDKs (25). Besides CDK5, olomoucine also targets CDK1 and CDK2 (46) and 
roscovitine additionally inhibits CDK1, CDK2, CDK7 and CDK9 (44). There are non-purine 
compounds like indirubins, paullones or aloisins (47-49) and also further developed 
roscovitine derivatives such as BA12 and BP14 (50) which show a greater potency than 
roscovitine, but without being more selective. Nevertheless, diseases are often multi-factorial 
and targeting more than one kinase might even be benefitial.  
 
1.4 Hypoxia-inducible factors 
Hypoxia-inducible factor-1 (HIF-1) is a heterodimeric transcription factor, which has recently 
been described to be a target of Cdk5 in mouse neuronal cells (51). It is composed of an 
oxygen-dependent α-subunit (HIF-1α or its paralogs HIF-2α and HIF-3α) and a constitutively 
expressed β-subunit (52, 53). Cells and tissues try to persist hypoxic conditions (around 1% 
O2) by the stabilization of HIF-1 thus inducing the transcription of target genes involved in 
angiogenesis, iron metabolism, glucose metabolism, cell proliferation and survival (53).  
1.4.1 HIF-1α: structure and function 
HIF-1α is a protein of 826 amino acids with a half-life of less than five minutes (54, 55). It is 
expressed ubiquitously and consists of different domains (Fig. 3): a basic-helix-loop-helix 
(bHLH) and PER-ARNT-SIM (PAS) domain, necessary to bind “HIF-response-elements” on 
the DNA and for dimerization with its β-subunit (52, 56). 
olomoucine (R)-roscovitine 
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Figure 3: Domains and post-translational modifications of HIF-1α.  
HIF-1α consists of 826 amino acids, divided into different domains: an N-terminal basic-helix-loop-
helix (red) and PER-ARNT-SIM (yellow) domain, important for either DNA binding or dimerization with 
its β-subunit (52, 56). Furthermore, there is an oxygen-dependent degradation domain (blue), involved 
in the regulation of HIF-1α degradation and two transactivation domains called N-TAD (dark green) 
and C-TAD (light green), important for transcriptional activation. In between those domains lies the 
inhibitory domain, which negatively regulates transactivation of HIF-1α. Additionally, a nuclear export 
signal (dark violet) and a nuclear localization signal (light violet) influence the localization of the 
transcription factor (52, 57-60). Post-translational modifications such as SUMOylation, hydroxylation, 
nitrosylation, nitrosation, acetylation and also phosphorylation are located in the C-terminal half and 
have been shown to be involved in the regulation of HIF-1α half-life and transcriptional activity (53, 61-
63). Abbreviations: bHLH, basic-helix-loop-helix; PAS, PER-ARNT-SIM; ODDD, oxygen-dependent 
degradation domain; N-TAD, N-terminal transactivation domain; NES, nuclear export signal; NLS, 
nuclear localization signal; C-TAD, C-terminal transactivation domain. 
 
Furthermore, it is composed of an oxygen-dependent degradation domain (ODDD) important 
for the degradation of the transcription factor by the ubiquitin-proteasome pathway under 
normoxia (57) as well as two transcriptional activation domains called N-TAD and C-TAD 
(58, 59, 64). For the regulation of HIF-1α localization, there are a nuclear localization signal 
(NLS) and a nuclear export signal (NES) (60). In between the two domains N-TAD and 
C-TAD lies the “inhibitory domain”. Its deletion has been shown to increase transactivation 
under normoxia (64). Post-translational modifications of HIF-1α like SUMOylation, 
acetylation, nitrosylation, nitrosation, ubiquitination, phosphorylation and also hydroxylation 
have been shown to influence HIF-1 stability and its transcriptional activity (53, 61-63). 
 
bHLH PAS ODDD N-TAD NES NLS C-TAD
inhibitory domain
1 826
S668 S696
phosphorylation
P402 P564
hydroxylation
N803
hydroxylation
C533 C800K532K477K391
SUMOylation
acetylation
nitrosylation nitrosation
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Figure 4: Oxygen-dependent degradation of HIF-1α .  
Under normoxic conditions the prolyl-hydroxylase (PHD) hydroxylates HIF-1α at proline 402 and 564, 
which enables the binding of the von-Hippel-Lindau protein (green). This promotes HIF-1α 
ubiquitinylation by an E3 ubiquitin-protein ligase finally leading to proteasomal degradation of the 
transcription factor. Furthermore, hydroxylation of asparagine 803 by factor inhibiting HIF-1 (FIH-1), 
prevents binding of the transcriptional coactivators p300 and CREB-binding protein (blue) and 
therefore transcriptional activation. Under hypoxic conditions, HIF-1α is not hydroxylated. VHL cannot 
bind and HIF-1α is not degraded. Binding of p300 and CBP transcriptionally activates HIF-1α (65). 
Abbreviations: bHLH, basic-helix-loop-helix; PAS, PER-ARNT-SIM; ODDD, oxygen-dependent 
degradation domain; N-TAD, N-terminal transactivation domain; NES, nuclear export signal; NLS, 
nuclear localization signal; C-TAD, C-terminal transactivation domain; VHL, von Hippel-Lindau protein; 
PHD, prolyl hydroxylase; CBP, cAMP response element-binding protein (CREB) – binding protein; 
FIH-1, factor-inhibiting-HIF-1. 
 
Under normoxic conditions, HIF-1α is degraded, which is mainly caused by oxygen-
dependent hydroxylation at the proline residues 402 and 564 by the prolyl hydroxylase (PHD) 
(Fig. 4). This enables the binding of the von Hippel-Lindau-protein (VHL), which promotes the 
ubiquitinylation of HIF-1α by an E3 ubiquitin ligase, targeting HIF-1α for proteasomal 
degradation. A further hydroxylation at the asparagine residue 803 by the factor-inhibiting-
HIF-1 (FIH-1) prevents the binding of the transcriptional coactivators p300 and CREB-binding 
bHLH PAS ODDD N-TAD NES NLS C-TAD
1 826
P402 P564
hydroxylation
N803
hydroxylation
PHD
normoxia
FIH-1
VHL
ubiquitinylation
proteasomal
degradation
p300/CBP
bHLH PAS ODDD N-TAD NES NLS C-TAD
1 826
hypoxia
VHL
p300/CBP
transcriptional
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protein (CREB). Under hypoxic conditions, HIF-1α is not hydroxylated, thus not degraded by 
the VHL pathway but transcriptionally activated by binding of p300/CBP. In consequence, 
HIF-1α translocates to the nucleus, dimerizes with its β-subunit and transcription of its target 
genes is induced (65). 
Besides HIF-1α, its paralog HIF-2α has also been shown to be a main actor in HIF 
transcriptional responses. It shares 48% amino acid sequence identity with HIF-1α and has 
overlapping functions. However its expression is mainly restricted to the lung, endothelium 
and carotid body (53, 66-68), but it has also been found in kidney, colonic epithelia, 
hepatocytes, macrophages, muscle cells and astrocytes (69).  The function of HIF-3α is quite 
different, since it is suggested to promote or inhibit the activity of other HIF complexes (70-
72). 
1.4.2 HIFs in angiogenesis and cancer 
Hypoxia is a key feature of many tumors. The induction of HIF-1 leads to an altered gene 
transcription of downstream targets to modulate processes such as glycolysis, proliferation, 
survival and invasion in order to overcome hypoxic stress (73). Furthermore, the expression 
of angiogenic factors like vascular-endothelial growth factor (VEGF), platelet-derived growth 
factor (PDGF) or placental growth factor (PLGF) is induced (74).  These factors enhance 
endothelial or smooth muscle cell proliferation, migration and survival to promote 
angiogenesis thereby ensuring a sufficient blood supply for the growing tumor (74-76). 
Several studies have already shown an involvement of HIF-1 in HCC tumorigenesis, 
progression and metastasis (57). There is compelling evidence, that HCCs overexpress 
HIF-1α and HIF-2α, which correlates with a poor patient prognosis (77, 78). Since hypoxic 
tumor areas are much more resistant to chemotherapy and radiation (79) and HIF-1 is 
involved in many processes promoting tumor growth (80), HIF-1 inhibition is an interesting 
treatment strategy. There are already inhibitors in clinical assessment, targeting HIF-1 mRNA 
transcription, down-regulation of protein synthesis, inhibiting HIF-1 stabilization or subunit 
heterodimerization, disturbing HIF-1 DNA binding or attenuating transcriptional activity (81, 
82). However, those inhibitors still have a very low specifity with undesirable side effects. 
Therefore, the identification of new targets involved in HIF-1 signaling would putatively help 
to overcome those limitations.  
  
1 INTRODUCTION 
19 
 
1.5 Aim of the study 
Hepatocellular carcinoma is a rapidly growing tumor reflecting a poor prognosis for patients 
(83). In many cases the diagnosis is in an already advanced stage, where treatment options 
are very limited (84). Since it is a highly vascularized tumor, anti-angiogenic therapy has 
become of increasing interest during the last years (23). First results are very promising, 
however, evasive mechanisms occur (11). 
Thus the aim of this study was to characterize CDK5 as a new potential target for anti-
angiogenic therapy of HCC. The involvement of CDK5 in angiogenesis of hepatocellular 
carcinoma was supposed to be analyzed in vitro and in vivo. Underlying mechanisms should 
be identified, focusing on hypoxic signaling, since hypoxia is a key feature of HCC. 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Compounds 
(R)-roscovitine and deferoxamine were obtained from Sigma-Aldrich, Germany. BA12 (2-[[[2-
[(4-aminocyclohexyl)amino]-9-cyclopentyl-purin-6-yl]amino]methyl]-4-chloro-phenol) and 
BP14 (N2-(4-aminocyclohexyl)-9-cyclopentyl-N6-[[6-(2-furyl)-3-pyridyl]methyl]purine-2,6-
diamine) were synthesized (85), dissolved and used (50) as previously described. 
 
2.1.2 Reagents and technical equipment 
Table 1: Reagents 
Reagent Producer 
Accustain paraformaldehyde Sigma-Aldrich, Taufkirchen, Germany 
AEC substrate Vector Laboratories, Burlingame, CA, USA 
Amphotericin B AppliChem, Darmstadt, Germany 
32P-γ-ATP Hartmann Analytic, Braunschweig, Germany 
Bovine serum albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
Bradford ReagentTM Bio-Rad, Munich, Germany 
high capacity cDNA Reverse Transcription 
Kit 
Applied Biosystems, San Francisco, CA,USA 
Collagenase A Roche, Mannheim, Germany 
Collagen G Biochrom AG, Berlin, Germany 
Complete® Roche diagnostics, Penzberg, Germany 
Dulbecco´s Modified Eagles Medium 
(DMEM) 
PAA Laboratories, Pasching, Austria 
Dimethylsulfoxide (DMSO) AppliChem, Darmstadt, Germany 
DharmaFECT Transfection reagent Thermo Scientific, Waltham, MA, USA 
EDTA disodium salt dehydrate Carl Roth, Karlsruhe, Germany 
Endothelial Cell Growth Medium (ECGM) 
with Supplement Mix C-39215 
PromoCell, Heidelberg, Germany 
Fetal calf serum (FCS) Biochrom AG, Berlin, Germany 
FluorSaveTM Reagent mounting medium Merck, Darmstadt, Germany 
Mayer’s Hematoxylin Solution Sigma-Aldrich, Taufkirchen, Germany 
Histone H1 (Type III from calf thymus) Sigma-Aldrich, Taufkirchen, Germany 
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M199 medium PAA Laboratories, Pasching, Austria 
Non-fat dry milk powder Carl Roth, Karlsruhe, Germany 
NucleofectorTM Kit T Lonza, Basel, Switzerland 
NucleofectorTM Kit HUVEC Lonza, Basel, Switzerland 
Sodium fluoride (NaF) Merck, Darmstadt, Germany 
Sodium orthovanadate (Na3VO4) ICN Biomedicals, Aurora, Ohio, USA 
Penicillin PAA Laboratories, Pasching, Austria 
Phenylmethylsulfonylfluoride (PMSF) Sigma-Aldrich, Munich, Germany 
Protein G agarose beads Sigma-Aldrich, Taufkirchen, Germany 
RNeasy Plus Mini Kit Qiagen, Hilden, Germany 
Streptomycin PAA Laboratories, Pasching, Austria 
TaqMan® Gene Expression Master Mix Applied Biosystems, San Francisco, CA,USA 
Targefect-HUVEC Targeting Systems, El Cajon, CA, USA 
Triton X-100 Merck, Darmstadt, Germany 
Tween®20  BDH/Prolabo®, Ismaning, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
Vectastain® Universal Elite ABC Kit Vector Laboratories, Burlingame, CA, USA 
 
Table 2: Technical equipment 
Name Producer 
AB7300 RT-PCR Applied Biosystems, Fosterer City,CA, USA 
Nitrocellulose membrane Hybond-ECLTM, Amersham Bioscience, 
Freiburg, Germany 
NucleofectorTMII Amaxa, Cologne, Germany 
Odyssey 2.1 LI-COR Biosciences, 
Lincoln, NE, USA 
Olympus DP25 camera Olympus, Hamburg, Germany 
Olympus BX41 microscope Olympus, Hamburg, Germany 
SpectraFluor PlusTM Tecan, Crailsheim, Germany 
Vi-Cell™ XR Beckman Coulter, Fullerton, CA, USA 
X-ray film (Super RX) Fuji, Düsseldorf, Germany 
LSM 510 META confocal microscope Zeiss, Jena, Germany 
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2.2 Cell Culture 
2.2.1 Solutions and reagents 
 
 
PBS (pH 7.4)  PBS+Ca2+/Mg2+ (pH 7.4) 
NaCl 123.3 mM  NaCl 136.9 mM 
Na2HPO4 10.4 mM  Na2HPO4 8.1 mM 
KH2PO4 3.2 mM  KH2PO4 1.5 mM 
H2O   KCl 2.7 mM 
   MgCl2 0.5 mM 
   CaCl2 0.7 mM 
   H2O  
 
ECGM  DMEM 
Supplement Mix 4.7%  FCS  10% 
FCS  10%  Penicillin 10.000 U/ml 
Amphotericin B 0.25%  Streptomycin 10% 
Penicillin  10.000 U/ml  DMEM  
Streptomycin 10%    
ECGM     
 
 
Trypsin/EDTA  Collagen G 
Trypsin 0.05%  Collagen G 0.001% 
EDTA 0.02%  PBS  
PBS     
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2.2.2 Endothelial cells 
Human umbilical vein endothelial cells (HUVECs) were isolated by digesting umbilical veins 
with collagenase A (0.1 g/L) for 45 min at 37°C. Prior to digestion, umbilical cords were 
washed with pre-warmed PBS+Ca2+/Mg2+. Finally, enzymatic reaction was stopped and cells 
were washed out the vein with stopping medium (M199 with 10% FCS). Freshly isolated 
HUVECs were centrifuged (180 g, 5 min, RT), resuspended in endothelial cell growth 
medium (ECGM) and seeded into a 25 cm2 flask. Cells were grown in ECGM supplemented 
with penicillin (10.000 U/mL) and streptomycin (10%) at 37°C and 5% CO2 until they were 
confluent. For passaging they were washed with PBS, detached with trypsin/ethylene 
diamine tetraacetic acid (EDTA, T/E) and centrifuged (180 g, 5 min, RT) after the addition of 
stopping medium. Afterwards the pellet was resuspended in ECGM and cells were 
transferred into a 75 cm2 flask. For all experiments, HUVECs were used in passage two and 
cell culture devices were coated with 0.001% Collagen G for 20 min prior to cell seeding. 
Human umbilical cords were kindly provided by local hospitals in accordance with the 
declaration of Helsinki. 
 
2.2.3 Cancer cells  
HUH7 cells were obtained from the Japanese Collection of Research Bioresources (JCRB). 
Cells were grown in Dulbecco´s Modified Eagle Medium (DMEM) containing 10% fetal calf 
serum (FCS) at 37°C and 5% CO2 until they were confluent. HUH7 cells were passaged 1:5 
twice a week. Cells were washed with PBS and detached with EDTA T/E. Finally, cells were 
seeded in DMEM with 10% FCS. For experiments, cells were used up to passage 30 and cell 
culture devices were coated with 0.001% Collagen G for 20 min prior to cell seeding. 
For long-term storage, confluent cells of a 150 cm2 flask were detached, centrifuged (180 g, 
5 min, RT) and resuspended in DMEM containing 20% FCS (not heat inactivated) and 10% 
dimethyl sulfoxide (DMSO). Aliquots in cryovials were stored at -80°C for 24 h and then 
transferred to liquid nitrogen. For thawing, cells were warmed and pre-warmed DMEM (10% 
FCS) was added. Afterwards, cells were centrifuged (180 g, 5 min, RT), resuspended in 
DMEM (10% FCS) and seeded into a 25 cm2 flask. Medium was changed the next day and 
cells were passaged at about 80% confluency as described above. 
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2.3 Transfection procedures 
HUVECs were either transfected with a Targefect/Virofect mixture used for siRNA or a 
Targefect/Peptide Enhancer mixture used for plasmids or by electroporation using 
NucleofectorTMII according to the manufacturer´s protocol. HUH7 cells were transfected with 
DharmaFECT Transfection reagent following the manufacturer´s instructions. 
2.3.1 CDK5 siRNA 
CDK5 was silenced with an equal mixture of two different ON-TARGETplus CDK5 siRNAs (J-
003239-09 and J-003239-10; Dharmacon, USA). ON-TARGETplus Non-targeting (nt) siRNA 
(D-001810-01; Dharmacon, USA) served as a control. Silencing efficiency was detected by 
western blot analysis. 
2.3.2 CDK5 shRNA 
In HUH7 cells CDK5 silencing by shRNA was performed as previously described (Ehrlich et 
al., Journal of Hepatology, in revision). CDK5 MISSION® shRNA Lentiviral Transduction 
Particles (Vector: pLKO.1-puro; SHCLNV-NM_004935; Clone ID: (1) TRCN0000021465, (2) 
TRCN0000021466, (3) TRCN0000021467, (4) TRCN0000194974, (5) TRCN0000195513; 
Sigma-Aldrich, Germany) and MISSION® pLKO.1-puro Non-Mammalian shRNA Control 
Transduction Particles (Sigma-Aldrich SHC002V, Germany) were used according to the 
manufacturer´s protocol. 
2.3.3 CDK5 overexpression 
HUVECs and HUH7 cells were cotransfected with 3 µg of CDK5-HA (Addgene 1872, van 
den Heuvel S. (86)) and P35 (Addgene 1347, Tsai Li-Huei), respectively. Transfection of 
3 µg of pCMV-Neo-Bam (Addgene, 16440, Vogelstein B. (87)) served as a control. 
Overexpression efficiency was detected after 24 h by western blot analysis. 
2.3.4 S687A and S687E HA-HIF-1α 
3 µg of alanine-mutated HIF (S687A) and glutamate-mutated HIF (S687E), generated by 
site-directed mutagenesis (see 2.12), were transfected into HUH7 cells followed by an 
incubation time of 24 h. Wildtype HIF-1α (wt, Addgene 18949, Kaelin W. (88)) and an empty 
pcDNA3 (Invitrogen, Germany) vector served as control (3 µg, 24 h). For Luciferase Assay 
0.3 µg of either pcDNA3, wt, S687A or S687E vector were used for transfection. 
2.3.5 pGL4.27(HIF-REluc2P), pGL4.74(hRluc/TK) 
HUH7 cells were transfected with 3 µg of the firefly luciferase containing vector pGL4.27(HIF-
REluc2P) (Promega, USA) and with 0.3 µg of the renilla luciferase containing vector 
pGL4.74(hRluc/TK) (Promega E692A, USA). 
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2.4 Immunohistochemistry 
Tissue sections from the HUH7 or HepG2 xenograft tumor model as well as from the 
orthotopic diethylnitrosamine-induced tumor model were stained using the Vectastain® 
Universal Elite ABC Kit for antibody detection. AEC served as chromogen. In between the 
different steps, slides were washed with PBS for 10 min at room temperature (RT). For 
deparaffinization slides were initially incubated for 15 min in xylol, followed by 20 min in 
100% and 20 min in 95% ethanol. For HIF-1α immunostaining, tissue sections were boiled in 
TRIS-ethylene glycol tetraacetic acid (EGTA) buffer (10mM Tris Base, 1mM EGTA, 0.05% 
Tween 20, pH 9.0) for 20 min to demask antigens whereas for CD31 staining slides were 
incubated with proteinase K (20 µg/ml) for 20 min at 37°C. Endogenous peroxidase was 
blocked by incubating the slides in 7.5% hydrogen peroxide for 10 min at RT. Sections were 
incubated with primary antibodies (HIF-1α, BD Biosciences 610958, 1:100; CD31, BD 
Biosciences, 553370, 1:100) for 1 h also at RT. Slides were counterstained with 
haematoxylin for 30 s and washed with water. Sections were embedded with FluorSaveTM 
Reagent mounting medium, covered with glass slips and pictures of the stained sections 
were taken with an Olympus BX41 microscope and an Olympus DP25 camera.  
 
2.5 Immunocytochemistry 
HUVECs were seeded into µ-slides and incubated until they were confluent. In between the 
different steps cells were washed with PBS+Ca2+/Mg2+. Cells were fixed with 4% para-
formaldehyde for 10 min at RT. Permeabilization of cells was done by treatment with 0.1% 
Triton X-100 (2 min, RT) followed by a blocking step in 0.2% BSA. Slides were incubated 
with primary antibodies (CDK5, Invitrogen AHZ0492, 1:100; HIF-1α, BD Biosciences 610958, 
1:100) for 1 h at RT. Afterwards the secondary antibody goat anti-mouse Alexa Fluor 488 
(Invitrogen A-11001, 1:400) was applied in combination with Hoechst (Sigma-Aldrich 
H33342, 5 µg/ml) and rhodamin-phalloidin (Invitrogen R 415, 1:400) for 30 min at RT. Finally, 
slides were embedded with FluorSaveTM Reagent mounting medium (Merck, Germany), 
covered with glass slips and pictures of the stained slides were obtained with Zeiss LSM 510 
META confocal microscope. 
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2.6 Western blot 
For western blot analysis, cells were washed twice with ice-cold PBS, lysis buffer was added 
and cells were frozen at -80°C. Afterwards, cells were scraped off on ice and transferred in 
Eppendorf cups, followed by centrifugation at 18620 g for 10 min at 4°C. Finally, protein 
amount was determined in supernatants by Bradford analysis and samples were adjusted to 
the lowest concentration. Proteins were separated by SDS-PAGE and transferred to 
nitrocellulose membranes by tank blotting. Afterwards, membranes were blocked in 5% non-
fat dry milk powder (Blotto) or 5% BSA for 2 h and incubated with primary antibodies 
overnight at 4°C. Dependent on the detection system the membranes were incubated with 
different secondary antibodies (2 h, RT): HRP-coupled antibodies were used for 
chemiluminescence detection by x-ray films whereas IR-fluorescent Reagent conjugated 
antibodies (Invitrogen, A – 21057, A – 21109; LI-COR IRDye®, 926-32210D, 926-32211D) 
were used to detect the bands via fluorescence signal at the Odyssey Infrared Imaging 
system version 2.1. 
 
Table 3: Primary antibodies 
Antigen Catalog No. Provider Dilution 
Actin Sc-1615 Santa Cruz 1:1000 in 5% Blotto 
β-Tubulin 2146 Cell Signaling 1:1000 in 5% BSA 
CDK2 sc-163 Santa Cruz 1:1000 in 5% Blotto 
CDK5 AHZ0492 Invitrogen 1:1000 in 5% Blotto 
CDK7 2916 Cell Signaling 1:1000 in 5% Blotto 
CDK9 sc-13130 Santa Cruz 1:1000 in 5% Blotto 
HA MMS-101R Covance 1:1000 in 5% Blotto 
HIF-1α 610958 BD Biosciences 1:750 in 5% Blotto 
HIF-2α MAB3472 Chemicon 1:1000 in 5% Blotto 
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Table 4: Secondary antibodies 
Antibody Catalog No. Provider Dilution 
Goat anti-mouse 
IgG1: HRP 
BZL07046 Biozol 1:1000 in 1% Blotto 
Goat anti-rabbit: 
HRP (H+L) 
111-035-
144 
Dianova 1:1000 in 1% Blotto 
Alexa Fluor® 680 
Goat anti-mouse IgG 
(H + L) 
A – 21057 Invitrogen 1:10.000 in 1% Blotto 
IRDye™ 800CW 
Goat 
anti-rabbit IgG (H + L) 
926-
32211D 
LI-COR 1:10.000 in 1% Blotto 
 
 
Table 5: Western blot solutions 
Solutions Composition 
Lysis buffer Tris/HCl 50 mM, NaCl 150 mM, Nonidet NP-40 1%, 
sodium deoxycholate 0.25%, SDS 0.1%, activated 
Na2VO4 300 µM, NaF 1 mM, β-glycerophosphate 3 mM, 
pyrophosphate 10 mM, Complete® EDTA free 4 mM, 
PMSF 1 mM, H2O2 600 µM in H2O 
5 x SDS sample 
buffer 
Tris/HCl (pH 6.8) 3.125 M, glycerol 50%, SDS 5%, 
DTT 2%, Pyronin Y 0.025% in H2O 
Separation gel 
10%/12% 
Rotiphorese™ Gel 30 33%/40%, Tris (pH 8.8) 375 mM, 
SDS 0.1%, TEMED 0.1%, APS 0.05% in H2O 
Stacking gel Rotiphorese™ Gel 30 17%, Tris (pH 6.8) 125 mM, 
SDS 0.1%, TEMED 0.2%, APS 0.1% in H2O 
Electrophoresis buffer Tris 4.9 mM, glycine 38 mM, SDS 0.1% in H2O 
Tank buffer Tris base 48 mM, glycine 39 mM, methanol 20% in H2O 
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2.7 Quantitative Real-time PCR 
Initially, RNA was isolated by RNeasy Kit according to the manufacturer´s protocol. 
Concentrations and purity of samples were determined with NanoDrop spectrophotometer. 
RNA was transcribed to cDNA with the high capacity cDNA Reverse Transcription Kit. Real-
time PCR was performed with 7300 Real Time PCR system. PCR components were 
supplied as master mix (TaqMan® Gene Expression Master Mix). For detecting the gene 
expression a set containing primer and probe for the specific gene was added (Applied 
Biosystems, USA). GAPDH served as housekeeping gene (Biomers, Germany). Calculation 
of the relative mRNA levels was done as described previously (89). 
Table 6: PCR primer and probes 
Primer/probe Catalog No. Provider Concentration 
EphrinA1 Hs00358886 Applied Biosystems 1 x 
VEGFA Hs00900055 Applied Biosystems 1 x 
VEGFR1 Hs01052961 Applied Biosystems 1 x 
    
 
2.8 Kinase activity assay 
Either immunoprecipitated CDK5 or recombinant CDK5/P35 (20 ng, Millipore 14-477, USA) 
was diluted in 50 µl kinase buffer (50 mM HEPES pH 7.0, 10 mM MgCl2, 1 mM DTT, 1 mM 
NaF, 1 mM Na3VO4, 1 mM PMSF, 3 mM β-glycerophosphate, 4 mM Complete® EDTAfree). 
As substrates Histone H1 (2.5 µg, Sigma-Aldrich H5505, USA) or HIF-1α (2.5 µg, Abcam 
ab48734, UK) were added. Finally 2 µM ATP and 10 µCi 32P-γ-ATP (Hartmann Analytic 
SRP-301, Braunschweig, Germany) completed the reaction mix. The samples were 
incubated at 30°C for 20 minutes. Then samples were prepared for SDS-Page gel 
electrophoresis by adding 5 x SDS Sample buffer and incubating them for 5 minutes at 95°C. 
Electrophoresis was run for 21 minutes at 100 V followed by another 35 minutes at 200 V. 
Phosphorylation of substrates was detected via autoradiography. An X-ray film was placed 
on the gel for 6 up to 48 h at -80°C. 
 
2.9 Immunoprecipitation 
Cells were lysed with a buffer containing 50 mM Tris/HCl pH 7.5, 250 mM NaCl, 1 mM EDTA 
pH 8.0, 10 mM NaF, 1x SIGMAFAST™ Protease Inhibitor. After scraping the cells off, they 
were incubated for about 30 min on ice. Samples were centrifuged (10.000 g, 10 min, 4°C) 
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and protein concentrations were adapted. 2 µg antibody (Cdk5; sc-173, Santa Cruz 
Biotechnology) were added per 500 µg protein followed by an incubation overnight at 4°C. 
Afterwards each sample was incubated with 25 µL packed Protein G Agarose beads (Sigma-
Aldrich, Germany) for 3 h at 4°C.  Finally further centrifugation steps followed (14.000 g, 
45 s, 4°C) in order to wash the beads. 
 
2.10 Co-immunoprecipitation 
Co-immunoprecipitation experiments were performed using the Pierce Crosslink Magnetic 
IP/Co-IP Kit (Thermo Scientific 88805, USA) according to the manufacturer´s protocol. 5 µg 
of CDK5 antibody (Invitrogen AHZ0492, USA) or HIF-1α antibody (BD Biosciences 610958, 
Germany) were used for immunoprecipitation. Mouse IGg1 (Abcam ab18443, UK) served as 
control antibody. 
 
2.11 Mass spectrometry 
In mass spectrometry experiments, phosphorylations on either recombinant HIF-1α (2.5 µg, 
Abcam ab48734, UK), incubated with 20 ng recombinant CDK5/P35 (Millipore, 14-477, USA) 
and 2 µM ATP at 30°C for 20 min or on HIF-1α immunoprecipitated in deferoxamine treated 
(6 h) HUH7 cells were analyzed. SDS-Page gel electrophoresis of the different samples was 
done followed by Coomassie staining. Gels were finally used for mass spectrometry analysis 
which was performed by Dr. T. Fröhlich from the Laboratory for Functional Genome Analysis 
(LAFUGA), Gene Center, University of Munich. 
 
2.12 Site-directed mutagenesis 
Point mutation in HIF-1α (Addgene 18949, Kaelin W. (88)) at serine 687 was generated by 
site-directed mutagenesis with primers that contain specific mismatches: 
5’GAACAGACAGAAAAATCTCATCCAAGAGCTCCTAACGTGTTATCTGTCGCTTTG and 
3’CAAAGCGACAGATAACACGTTAGGAGCTCTTGGATGAGATTTTTCTGTCTGTTC 
primers were used for an alanine mutation (S687A) whereas 
5’GAACAGACAGAAAAATCTCATCCAAGAGAGCCTAACGTGTTATCTGTCGCTTTG and 
3’CAAAGCGACAGATAACACGTTAGGCTCTCTTGGATGAGATTTTTCTGTCTGTTC were 
used for a glutamate mutation (S687E). The mutated codons are underlined. Template DNA 
of mutagenesis PCR was digested with DpnI (New England Biolabs R0176S, Germany). The 
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PCR-generated mutants were transformed into competent E.coli and grown on selective agar 
(Ampicillin). Mini-prep of selected clones was performed according to the manufacturer´s 
instructions (Qiagen 27106, Germany). The nucleotide sequences of isolated plasmids were 
verified by sequence analysis performed by MWG Eurofins (Germany) followed by maxi-prep 
of the correctly mutated clones (Qiagen 12362, Germany) according to the manufacturer´s 
protocol. 
 
2.13 Dual-Luciferase assay 
HUH7 cells were seeded into a 96-well plate and transfected with pGL4.27(HIF-REluc2P) 
and pGL4.74(hRluc/TK) (Promega, USA). The activity of firefly and renilla luciferases was 
determined using the Dual-Luciferase Reporter Assay System (Promega E1910, USA) 
according to the manufacturer´s instructions. For measurement, lysed cells were transferred 
into a white 96-well plate. Luminescence was detected with Orion II Microplate Luminometer 
(Berthold Detection Systems). 
 
2.14 Hypoxic chamber assay 
Cells were cultivated in a hypoxic chamber (Don Whitley Scientific, Whitley H35 
Hypoxystation, UK) at 1% O2 in carbonate-free medium (Biochrom AG L-15 Leibovitz 
Medium, Germany) supplemented with 10% FCS and penicillin (10.000 U/mL) as well as 
streptomycin (10%). Control cells were cultivated at around 21% oxygen in a CO2 free 
incubator. After 24 h cells were lysed and western blot analysis was performed.  
 
2.15 In vivo experiments 
All experiments were performed according to Austrian guidelines or German legislation for 
the protection of animals and approved by the local government authorities. Experiments 
were carried out as described previously (Ehrlich et al., Journal of Hepatology, in revision, 
(50)). 
HUH7 xenograft tumor model: 3.3*106 of either HUH7 cells or CDK5 knockdown HUH7 cells 
were subcutaneously injected in 100 µL PBS into the flank of female SCID mice (8–10 
weeks). The tumor progression was regularly controlled. Roscovitine treated mice were 
injected intraperitoneally (150 mg/kg, 100 µL; solvent: PBS/DMSO/Solutol 17:1:2). Seven 
days after tumor implantation application of roscovitine started and daily injections were 
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carried on for seven days. Control mice received solvent only. This in vivo experiment was 
performed by Dr. J. Liebl and B. Hager. 
HepG2 xenograft tumor model: 5.0*106  HepG2 cells were subcutaneously injected into SCID 
mice (Harlan Laboratories, San Pietro, Italy). Mice were injected intraperitoneally with either 
5 mg/kg BA12 or 1 mg/kg BP14 in 100 µl of 0.01% DMSO every day (17 days). Control mice 
received DMSO only. This in vivo experiment was performed by the group of Prof. Mikulits at 
the University of Vienna. 
Diethylnitrosamine-induced orthotopic tumor model: For tumor development 14-day-old male 
C57BL/6J mice were intraperitoneally injected with a single dose of diethylnitrosamine (DEN, 
25 mg/kg). After eight month of tumor growth, mice were treated with compounds in three 
cycles for 10 days with a release of the compounds in between the cycles for seven days. 
Mice were injected intraperitoneally with either 5 mg/kg BA12 or 1 mg/kg BP14 in 100 µL of 
0.01% DMSO. Control mice received DMSO only. This in vivo experiment was performed by 
the group of Prof. Mikulits at the University of Vienna. 
 
2.16 Statistical analysis 
Data are expressed as means ± standard error of mean (SEM) or as Whisker plots with lines 
indicating maximum and minimum values. The statistical significances were determined 
using GraphPad Prism 5. Statistical significance is assumed if p ≤ 0.05. Statistical tests are 
indicated in the corresponding figure legends. 
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3. RESULTS 
 
3.1 Pharmacological CDK5 inhibition significantly inhibits angiogenesis in 
vivo 
Recent studies reported that CDK5 plays a crucial role during angiogenesis (31). Since 
CDK5 is highly expressed in hepatocellular carcinoma (Ehrlich et al., Journal of Hepatology, 
in revision) and HCC is one of the most vascularized solid tumors (17), the effect of CDK5 
inhibition on vascularization was investigated in different liver tumor models. CD31 staining 
of HUH7 tumors from mice treated with roscovitine (rosco), a well-established CDK5 inhibitor 
(44), revealed a reduced microvascular density as compared to solvent controls. This result 
was also confirmed by CD34 staining, another well-known endothelial cell marker, which is 
additionally expressed on hematopoietic stem cells (90) (Fig. 5). The in vivo experiments 
were performed by Dr. J. Liebl and B. Hager. 
 
Figure 5: Pharmacological inhibition of CDK5 reduces vascular density in a HUH7 
xenograft tumor model. 
Immunostaining for CD31 (red) or CD34 (red) and haematoxylin (blue, nuclei) of HCC tumors grown in 
SCID mice either treated with solvent or roscovitine is shown. The microvessel density (MVD) per 
square mm was determined. Scale bars: 50 µm. Non-parametric t-test on Mann-Whitney, * p < 0.05, 
n = 8. Whisker lines indicate maximum and minimum values. Immunostaining was performed by Dr. S. 
Ehrlich. 
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Furthermore, the effect of the two roscovitine derivatives BA12 and BP14 on vascular density 
was investigated in a diethylnitrosamine (DEN)-induced orthotopic mouse tumor model (Fig. 
6A) as well as in a HepG2 xenograft mouse tumor model (Fig. 6B).  
 
Figure 6: Pharmacological inhibition of CDK5 reduces vascular density in a 
diethylnitrosamine-induced orthotopic liver tumor model as well as in a HepG2 
xenograft tumor model. 
(A) Immunostaining for CD31 (red) and haematoxylin (blue, nuclei) of DEN-induced tumors grown in 
mice either treated with solvents or the roscovitine derivatives BA12 and BP14. The microvessel 
density per square mm was determined. Scale bars: 50 µm. Non-parametric t-test on Mann-Whitney, 
* p < 0.05, n = 5. Whisker lines indicate maximum and minimum values. (B) Immunostaining for CD31 
(red) and haematoxylin (blue, nuclei) of HepG2 tumors grown in SCID mice either treated with 
solvents or the roscovitine derivatives BA12 and BP14. The microvessel density per square mm was 
determined. Scale bars: 50 µm. n = 4. Whisker lines indicate maximum and minimum values. 
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Tumors were kindly provided by the group of Prof. Wolfgang Mikulits from the Department of 
Medicine I of the Medical University of Vienna. The microvessel density was analysed by 
CD31 immunostaining. The vascular density in tumors of mice treated with BA12 and BP14 
was reduced as compared to solvent controls (Fig. 6) in both models. 
 
3.2 HIF protein level is regulated by CDK5 in endothelial cells 
In further studies the signaling mechanism putatively responsible for the effects on 
angiogenesis was investigated. Hypoxia is often a key feature of tumor progression, 
promoting the expression of angiogenic factors by hypoxia inducible factors (91). Therefore, 
the effect of either CDK5 inhibition or overexpression on HIF-1α was examined. Hypoxia was 
simulated by the iron chelator deferoxamine (DFO) or in a hypoxic chamber (1% O2). Both, 
pharmacological inhibition of CDK5 by roscovitine and siRNA mediated down-regulation, 
decreased the DFO-induced protein level of HIF-1α in human umbilical vein endothelial cells 
(HUVECs) (Fig. 7).  
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Figure 7: DFO-induced protein level of HIF-1α is reduced upon CDK5 inhibition in 
endothelial cells. 
(A) Immunoblots of lysates from HUVECs. CDK5 was either inhibited pharmacologically by roscovitine 
pretreatment for 30 minutes (30 µM) or transiently down-regulated by siRNA. Lysates were probed 
with antibodies for HIF-1α, CDK5, Actin or β-Tubulin. To simulate hypoxia HUVECs were treated with 
100 µM of the iron chelator deferoxamine for six hours. The quantifications of the corresponding 
immunoblots are shown. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars represent 
mean ± SEM. (B) Immunostaining of HUVECs for HIF-1α, Actin and nuclei. Cells were either 
untreated or treated with roscovitine or transfected with nt siRNA or CDK5 siRNA. Scale bars: 20 µm. 
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This was also confirmed for HUVECs cultivated at 1% O2 in a hypoxic chamber (Fig. 8). In 
line with these findings, overexpression of P35/CDK5, led to a significantly increased HIF-1α 
protein level under normoxic conditions (Fig. 9).  
 
Figure 8: Hypoxic chamber-induced HIF-1α protein level is reduced upon CDK5 
inhibition in endothelial cells. 
Immunoblots of lysates from HUVECs either incubated at 21% or 1% oxygen for 24 hours. (A) CDK5 
was pharmacologically inhibited by roscovitine. Lysates were probed with antibodies for HIF-1α, CDK5 
and β-Tubulin. Below the quantifications of the corresponding immunoblots are shown. One Way 
ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars represent mean ± SEM. (B) CDK5 was 
silenced with CDK5 siRNA. Lysates were probed with antibodies for HIF-1α, CDK5 and β-Tubulin. 
Below the quantifications of the corresponding immunoblots are shown. One Way ANOVA on 
Newman-Keuls, * p < 0.05, n = 3. Error bars represent mean ± SEM. 
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Figure 9: The protein level of HIF-1α  correlates with CDK5 protein level in 
endothelial cells also under normoxia. 
Immunoblot shows protein level of HIF-1α in HUVECs either transfected with a control plasmid or with 
a P35/CDK5 vector, cultivated under normoxic conditions (21% oxygen). Quantification is shown. One 
Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars represent mean ± SEM.  
 
Since not only overexpression of HIF-1α but also of HIF-2α is a common feature in 
hepatocellular carcinoma (83), the effect of CDK5 inhibition on the subunit HIF-2α was 
additionally analysed. Indeed, roscovitine treatment of HUVECs also led to a decrease of the 
DFO-induced protein level of HIF-2α (Fig. 10). 
 
Figure 10: HIF-2α  protein level is reduced by CDK5 inhibition in endothelial cells. 
Immunoblot for HIF-2α, HIF-1α and β-Tubulin of HUVECs treated with 30 µM roscovitine. Graph 
displays the quantification. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars 
represent mean ± SEM. 
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In further experiments the influence of other CDKs on the protein level of HIF-1α was 
assessed. Whereas siRNA mediated down-regulation of CDK2 also led to a significant 
decrease of the DFO-induced protein level of HIF-1α, CDK7 and CDK9 seemed to have no 
strong influence on the protein amount of the transcription factor (Fig. 11). 
 
Figure 11: CDK2 inhibition also decreases HIF-1α protein level in endothelial 
cells. 
(A) Immunoblots of lysates from HUVECs either transfected with CDK2, CDK7 or CDK9 siRNA. 
Lysates were probed with antibodies for HIF-1α, β-Tubulin and the corresponding kinase to check the 
knockdown. To simulate hypoxia, cells were stimulated with 100 µM deferoxamine for six hours. The 
quantifications of the corresponding immunoblots are shown. One Way ANOVA on Newman-Keuls, 
* p < 0.05, n = 3. Error bars represent mean ± SEM. (B) Immunostaining of HUVECs for HIF-1α, Actin 
and nuclei. Cells were either transfected with non-target siRNA or with CDK2, CDK7 or CDK9 siRNA. 
Scale bars: 20 µm. 
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3.3 The transcription of HIF target genes is down-regulated in endothelial 
cells upon CDK5 inhibition  
To clarify whether CDK5 also influences the transcriptional activity of HIF, quantitative real-
time PCR analysis of HIF target genes VEGFA and VEGFR1 was performed in HUVECs. 
Both genes are known to be involved in the regulation of angiogenesis (2). The hypoxia-
induced increase of the VEGFA and VEGFR1 mRNA levels was significantly decreased after 
pharmacological CDK5 inhibition (Fig. 12A), as well as upon siRNA mediated down- 
regulation (Fig. 12B) of CDK5. 
 
Figure 12: Pharmacological inhibition or knockdown of CDK5 reduces the 
transcription of HIF target genes in endothelial cells.  
(A) Real-time PCR analysis of the HIF target genes VEGFA and VEGFR1 is shown. HUVECs were 
either untreated or treated with roscovitine. Hypoxia was simulated by treating the cells with 100 µM 
deferoxamine for six hours. Graphs display the fold change in percent. One Way ANOVA on Newman-
Keuls, * p < 0.05, n = 3. Error bars represent mean ± SEM. (B) Real-time PCR of VEGFA and 
VEGFR1 for HUVECs either transfected with nt siRNA or CDK5 siRNA, treated with 100 µM 
deferoxamine for six hours. Graphs display the fold change in percent. One Way ANOVA on Newman-
Keuls, * p < 0.05, n = 3. Error bars represent mean ± SEM. 
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3.4 HIF protein level is regulated by CDK5 in hepatocellular carcinoma cells 
In order to investigate the effect of CDK5 inhibition on HIF in hepatocellular carcinoma cells 
(HUH7), CDK5 was either inhibited by roscovitine or stably down-regulated by shRNA. The 
knockdown level of two independent HUH7 clones (CDK5-1: CDK5 knockdown clone 1, 
CDK5-4: CDK5 knockdown clone 4) is shown in Fig. 13.  
 
Figure 13: CDK5 knockdown clones 1 and 4 show a significantly reduced CDK5 
protein level in liver tumor cells. 
Immunoblot for CDK5 and β-Tubulin of lysates from HUH7 cells transfected with CDK5 shRNA 
(CDK5-1: clone 1, CDK5-4: clone 4). Graph displays quantification of the knockdown level. 
 
In parallel to the results in HUVECs, CDK5 inhibition either by roscovitine or by stable shRNA 
mediated down-regulation led to a reduction of the protein level of HIF-1α in DFO treated 
HUH7 cells. This result could be confirmed comparing the two independent HUH7 clones, 
CDK5-1 and CDK5-4, cultivated in a hypoxic chamber at 1% O2 (Fig. 14).  
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Figure 14: HIF-1α  protein level correlates with CDK5 protein level in liver tumor 
cells. 
(A) Immunoblots of HIF-1α, CDK5 and β-Tubulin in HUH7 lysates. CDK5 was either inhibited by 
roscovitine pretreatment for 30 minutes (30 µM) or stably down-regulated by CDK5 shRNA. HUH7 
cells were treated with 100 µM deferoxamine for six hours. The quantification is shown below the 
corresponding blot. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars represent mean 
± SEM. (B) Immunoblots of either untreated or roscovitine pretreated HUH7 cells (30 µm, 30 minutes) 
or nt shRNA and CDK5 shRNA HUH7 cells (two clones CDK5-1 and CDK5-4) are shown. Cells were 
incubated at 21% or 1% oxygen for 24 hours. Samples were probed for HIF-1α and β-Tubulin. The 
graphs below display the quantification of the immunoblots. One Way ANOVA on Newman-Keuls, 
* p < 0.05, n = 3. Error bars represent mean ± SEM. 
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Additionally, under normoxic conditions P35/CDK5 overexpression led to an increase of 
HIF-1α protein level (Fig. 15) again indicating a direct correlation between CDK5 and HIF-1α 
in HUH7 cells.  
 
Figure 15: The protein level of HIF-1α correlates with CDK5 protein level in liver 
tumor cells also under normoxia. 
Immunoblot shows the protein level of HIF-1α, CDK5 and β‑Tubulin in HUH7 cells cultivated under 
normoxic conditions (21% oxygen). Cells were either transfected with a control plasmid or with a 
P35/CDK5 vector. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars represent mean 
± SEM. 
 
Furthermore, roscovitine treatment of HUH7 cells also led to a decrease of the DFO-induced 
protein level of HIF-2α (Fig. 16). 
 
Figure 16: HIF-2α  protein level is reduced by CDK5 inhibition in liver tumor cells.  
Immunoblot for HIF-2α, HIF-1α and β-Tubulin of HUH7 cells, either left untreated or treated with 30 µm 
roscovitine, 30 minutes prior to deferoxamine treatment (100 µM, six hours). Graph displays the 
quantification. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars represent mean ± 
SEM.  
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3.5 The transcription of HIF target genes and transcriptional activation of HIF 
is down-regulated in HCC cells upon CDK5 inhibition  
Interestingly, it could be shown that not only the protein level of the transcription factor 
HIF-1α is influenced by CDK5 inhibition, but also the transcription of its target genes VEGFA 
and EphrinA1. VEGFA and EphrinA1 are both important modulators of angiogenic processes 
(1, 92) and EphrinA1 has been shown to be highly upregulated in HCC, promoting cell 
growth of hepatocellular tumors (92). Both genes were significantly down-regulated upon 
CDK5 inhibition by roscovitine as well as in stable CDK5 knockdown clone 1 (Fig. 17).  
 
Figure 17: Pharmacological inhibition or distinct knockdown of CDK5 reduces the 
transcription of HIF target genes in liver tumor cells.  
(A) Real-time PCR analysis of VEGFA and EphrinA1 is shown. HUH7 cells were either left untreated 
or treated with 30 µm roscovitine, 30 minutes prior to deferoxamine treatment (100 µM, six hours). 
Graphs display the fold change in percent. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. 
Error bars represent mean ± SEM. (B) Real-time PCR of VEGFA and EphrinA1 of nt shRNA HUH7 
and CDK5 shRNA HUH7 cells is shown. Hypoxia was simulated with 100 µM deferoxamine for six 
hours. Graphs display the fold change in percent. One Way ANOVA on Newman-Keuls, * p < 0.05, 
n = 3. Error bars represent mean ± SEM. 
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Additionally, these data were confirmed in a luciferase assay which revealed a significant 
lower transcriptional activity of HIF-1α in roscovitine treated cells and in CDK5 knockdown 
clone 1 in comparison to control (Fig. 18). 
 
 
Figure 18: Pharmacological inhibition or distinct knockdown of CDK5 reduces the 
transcriptional activity of HIF-1α in liver tumor cells.  
Luciferase assay of HUH7 cells, transfected with a firefly luciferase vector pGL4.27(HIF-REluc2P) and 
a renilla luciferase vector pGL4.74(hRluc/TK) is shown. CDK5 was either inhibited pharmacologically 
with roscovitine or down-regulated by distinct knockdown. The graphs show the relative light units 
(RLU) of firefly/renilla in percent. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars 
represent mean ± SEM. 
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3.6 CDK5 inhibition leads to a reduction of HIF-1α in vivo 
The influence of CDK5 inhibition on HIF-1α in vivo was assessed in a HUH7 xenograft tumor 
model. Figure 19A shows a significant reduction in the area of HIF-1α positive cells for 
tumors of mice treated with roscovitine. Accordingly, this effect could also be observed for 
tumors established from stable CDK5 shRNA HUH7 cells (Fig. 19B). 
 
Figure 19: Pharmacological inhibition or distinct knockdown of CDK5 reduces the 
protein level of HIF-1α  in a HUH7 xenograft tumor model.  
(A) Immunostaining of HIF-1α (red) and haematoxylin (blue, nuclei) of HCC tumors grown in SCID 
mice either treated with solvents or roscovitine is shown. The graph shows the quantification of the 
tumor area with HIF-1α positive cells of representative tissue sections from each tumor. Scale bars: 
200 µm. Non-parametric t-test on Mann-Whitney, * p < 0.05, n = 8. Whisker lines indicate maximum 
and minimum values. (B) Immunostaining of HIF-1α (red) and haematoxylin (blue, nuclei) of tumors 
from nt shRNA HUH7 and CDK5 shRNA HUH7 cells grown in SCID mice is shown. The graph shows 
the quantification of the tumor area with HIF-1α positive cells of representative tissue sections from 
each tumor. Scale bars: 200 µm. Non-parametric t-test on Mann-Whitney, * p < 0.05, n = 11. Whisker 
lines indicate maximum and minimum values. 
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3.7 CDK5 directly interacts with HIF-1α preventing its proteasomal 
degradation  
To get a better insight into how CDK5 might regulate angiogenesis in HCC via HIF-1α, the 
focus was put on the interaction mechanism between CDK5 and the transcription factor. In a 
first step, co-immunoprecipitation experiments revealed a direct interaction between CDK5 
and HIF-1α (Fig. 20A). Furthermore, it could be shown that proteasome inhibition by MG132 
totally rescues the effect of CDK5 inhibition on HIF-1α (Fig. 20B).  
 
Figure 20: CDK5 directly interacts with HIF 1α and protects it from proteasomal 
degradation.  
(A) Co-immunoprecipitation of CDK5 and HIF-1α in HUH7 cells, treated with 100 µM deferoxamine for 
six hours. n = 3 (B) Immunoblot for HIF-1α and β-Tubulin of lysates from HUVECs, either transfected 
with nt siRNA or CDK5 siRNA is shown. Cells were left untreated or treated with 1 µM of the 
proteasomal inhibitor MG132, 30 minutes prior to deferoxamine treatment (100 µM, six hours). The 
quantification summarizes the ratio of HIF-1α and β-Tubulin of three independent experiments. One 
Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars represent mean ± SEM.  
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3.8 CDK5 phosphorylates HIF-1α at serine 687 leading to the stabilization of 
the transcription factor 
The previous findings suggest that CDK5 directly phosphorylates HIF-1α thereby promoting 
its stabilization. In fact, it was shown in this study in a kinase activity assay that recombinant 
P35/CDK5 phosphorylates recombinant HIF-1α in vitro (Fig. 21).  
 
 
Figure 21: Recombinant P35/CDK5 phosphorylates recombinant HIF-1α in vitro.  
CDK5 kinase activity assay with recombinant P35/CDK5 and HIF-1α is shown. The enzymatic transfer 
of 32P from [ϒ-32P] ATP to HIF-1α was measured. P-Histone H1 served as control. Samples were 
either left untreated or treated with 100 µM roscovitine, n = 3. 
 
Based on these data, mass spectrometry experiments were performed in order to find the 
CDK5 phosphorylation site responsible for HIF-1α stabilization. Recombinant P35/CDK5 was 
incubated with recombinant HIF-1α and ATP and the phosphorylations on HIF-1α were 
analyzed. Interestingly, serine 687, which lies within the CDK5 motif aa 685-688, was 
identified to be phosphorylated by recombinant P35/CDK5. In a further mass spectrometry 
approach, HIF-1α, immunoprecipitated from DFO treated HUH7 cells, also displayed a 
phosphorylation on serine 687 (Fig. 22A, mass spectra see supplementary data). To finally 
confirm the importance of phosphorylated serine 687 for the stability of HIF-1α, point 
mutations of this site to either alanine (S687A) or glutamate (S687E) were generated in HA-
HIF-1α with site-directed mutagenesis (Fig. 22B, sequences see supplementary data). 
Alanine mutation was performed to prevent phosphorylation at S687 whereas glutamate 
mutation was used to simulate phosphorylation at this site.  
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Figure 22: CDK5 phosphorylates HIF-1α  at serine 687. 
(A) Result of mass spectrometry analysis of CDK5 phosphorylation sites on HIF-1α is shown. CDK5 
phosphorylation sites on either recombinant HIF-1α (in vitro) or immunoprecipitated HIF-1α (in vivo) 
from HUH7 cells, treated with deferoxamine for 6 h, are displayed. Phosphorylated sites are 
underlined, CDK5 motif is indicated in bold. As negative control, non-phosphorylated HIF-1α was 
analyzed. (B) Peptide sequence of wildtype HIF-1α (wt) versus alanine (S687A) and glutamate 
(S687E) substituted HA-HIF-1α is shown. Phosphorylation site of interest (S687) is underlined, CDK5 
motif is indicated in bold. 
 
In fact, western blot analysis in HUH7 cells revealed, that S687A-HA-HIF-1α is less stable 
than wt HA-HIF-1α whereas S687E-HA-HIF-1α shows an increased stability (Fig. 23A). 
Additionally, a luciferase assay confirmed this result showing a decreased transcriptional 
activity of S687A-HA-HIF-1α compared to wt HA-HIF-1α and an increased transcriptional 
activity for S687E-HA-HIF-1α (Fig. 23B). 
  
A
in vitro:
HIF-1α: 640SPSPTHIHKETTSATSSPYR660
680EKSHPRSPNVLSVALSQRTT700
in vivo:
HIF-1α: 680EKSHPRSPNVLSVALSQRTT700
B
wt HIF-1α: 680EKSHPRSPNVLSVALSQRTT700
S687A:                                 A
S687E:                             E
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Figure 23: Phosphorylation of HIF-1α  at serine 687 by CDK5 promotes the stability 
of the transcription factor.  
(A) Immunoblot of HUH7 cells either transfected with a control plasmid (pcDNA), wt HA-HIF-1α, 
S687A or S687E HA-HIF-1α is shown. Lysates were probed for HA and β-Tubulin. The graph displays 
the quantification of the immunoblots. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error 
bars represent mean ± SEM. (B) Dual-Luciferase assay of HUH7 cells either transfected with a control 
plasmid (pcDNA) or with wt HA-HIF-1α, S687A or S687E HA-HIF-1α is shown. Graph displays the 
RLU in percent. One Way ANOVA on Newman-Keuls, * p < 0.05, n = 3. Error bars represent mean ± 
SEM. 
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4. DISCUSSION 
 
4.1 Targeting HIFs via CDK5 inhibition in cancer therapy 
In the present study the serine/threonine kinase CDK5 was identified as an interesting new 
target for anti-angiogenic therapy of HCC. CDK5 inhibition was demonstrated to lead to a 
significant decrease of the protein level of HIF-1α and HIF-2α as well as the transcription of 
HIF target genes such as VEGFA in endothelial and liver cancer cells. Upon CDK5 inhibition 
angiogenesis in different kinds of HCC mouse models was significantly reduced.  
These results are consistent with the findings of Xie et al. who already showed a correlation 
of CDK5 and VEGF expression in pituitary adenomas (33). CDK5 is not only involved in 
several neuronal diseases as Alzheimer´s disease (45) but also in different types of cancer 
like medullary thyroid carcinoma (30) and hepatocellular carcinoma (Ehrlich et al., Journal of 
Hepatology, in revision). Haider et al. currently showed that CDK inhibitors BA12 and BP14 
have strong antitumorigenic effects on hepatocellular carcinomas (50). In line with the 
findings of this study, the CDK inhibitor P276-00 has been demonstrated to inhibit HIF-1α 
inducing G2/M arrest under hypoxia in prostate cancer cells also showing anti-angiogenic 
efficacy (93). Therefore, CDK5 inhibition might be of great interest as new therapeutic 
strategy, especially in the treatment of highly vascularized cancers. 
 
4.2 Anti-angiogenic therapy as treatment strategy for hepatocellular 
carcinoma  
Hypervascularity is a characteristic feature of hepatocellular carcinoma and an increase in 
microvascular density is associated with a poor prognosis (23). Angiogenesis is not only a 
fundamental step for tumor growth but also for invasion and metastasis (94). In this study, 
the efficacy of CDK5 inhibition on angiogenesis in different hepatocellular carcinoma mouse 
models was demonstrated. This is especially interesting, because hepatocellular carcinoma 
is the third leading cause of cancer-related death in the world (12) with a high resistance to 
systemic therapies even after aggressive local therapy. Therefore, there is an urgent need 
for new therapeutic options (95). In recent years anti-angiogenic therapy has become of 
increasing importance in preclinical and clinical assessments (23). Although there is 
evidence in pre-clinical studies, that anti-angiogenic therapy inhibits the growth of HCC (96), 
many of the results could not be confirmed in clinical trials (23). Currently used anti-
4 DISCUSSION 
54 
 
angiogenic drugs mainly target the VEGF pathway (1, 9). However, the process of 
angiogenesis does not depend on a single molecule. Zeng et al. even suggest a 
VEGF/angiopoietin-independent tumor blood supply in HCC (97). Additionally, there are 
several evasive mechanisms to anti-angiogenic VEGF therapy, like the activation of 
alternative pro-angiogenic pathways e.g. via hypoxia-inducible transcription factors (3).  
 
4.3 Relevance of HIF-1α and HIF-2α inhibition in HCC 
Hypoxia inducible factors are key players in cancer progression. They are activated under 
hypoxic conditions enhancing proliferation, angiogenesis, metastasis, chemoresistance and 
radioresistance of HCC (98). In this study, a significant down-regulation of the protein level of 
both subunits, HIF-1α and HIF-2α, as well as a reduction in the transcriptional activity was 
shown. Since it has already been demonstrated for hepatocellular tumor spheroids that 
knockdown of just one subunit, HIF-1α or HIF-2α, leads to the up-regulation of the other 
subunit, thereby eliminating survival advantages by dysregulating autophagy and apoptosis, 
targeting HIFs via CDK5 inhibition seems to be quite promising. Furthermore, a correlation 
between the oxygen-dependent subunit HIF-1α and tumor size as well as a poor prognosis of 
HCC has already been shown (17). Moreover, Bangoura et al. showed a link between HIF-2α 
expression and HCC tumor size, capsule infiltration, portal vein invasion and necrosis. In line 
with the findings of this study, they even suggest an involvement of HIF-2α in HCC tumor 
angiogenesis, since HIF-2α overexpression correlated with increased VEGF levels (77). 
Therefore, targeting HIF-1α as well as HIF-2α via CDK5 inhibition, could probably lead to a 
survival advantage of HCC patients, especially since HIF-1α and HIF-2α are both 
overexpressed in HCC (83). Concluding, HIFs are interesting candidates for HCC treatment 
and some HIF inhibitors are in clinical trials or already approved (82). 
 
4.4 CDK5 phosphorylates HIF – the importance of post-translational 
modifications in the regulation of HIF stability and activation 
Although an involvement of CDK5 in hypoxic signaling was already shown in mouse 
neuronal cells (51), the underlying mechanism behind was so far largely unknown. Post-
translational modifications such as hydroxylation (53), ubiquitination (61), acetylation (99), S-
nitrosylation (63) and also phosphorylation (62) have already been shown to influence HIF-1 
half-life and its transcriptional activity. Furthermore an involvement of tyrosine and 
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serine/threonine kinases in phosphorylating HIF-1α has previously been demonstrated, as 
their inhibition led to a decreased HIF expression, protein level and activity (100).  
In this study it has been shown that CDK5 directly phosphorylates HIF-1α at serine 687 in 
human liver cancer cells promoting its stabilization. Even though phosphorylation of HIF-1α is 
known to influence its transcriptional activity, subcellular localization, protein-protein 
interaction and stability (79), only few phosphorylation sites responsible for HIF-1α 
stabilization have been identified so far. Warfel et al. demonstrated that in colorectal cancer 
HIF-1α is phosphorylated at serine 668 by CDK1 enhancing the stability of the transcription 
factor (101). Additionally, phosphorylation of HIF-1α at serine 696 by the serine/threonine 
kinase ataxia telangiectasia mutated (ATM) has been shown to stabilize HIF-1α down- 
regulating mTOR-complex1 signaling in pediatric solid tumors (102). These two 
phosphorylation sites lie within the inhibitory domain (aa 576-785) of HIF-1α that inhibits 
transactivation of the transcription factor (64). Interestingly, the identified phosphorylation site 
at serine 687, which lies within the CDK5 consensus motif K/RT/SPXK (103, 104) in the 
inhibitory domain, is located in close proximity to these sites. The data of this study indicate 
that phosphorylation at serine 687 stabilizes HIF-1α and induces its transcriptional activity 
thereby putatively overcoming the inhibitory function of this domain. Nevertheless, other 
post-transcriptional modifications certainly also contribute to HIF-1α stabilization and it is still 
not clear, which mechanism is responsible for HIF-2α stabilization. So there might be further 
phosphorylation sites yet to be identified.  
 
4.5 Involvement of CDK2 in HIF stabilization 
This study demonstrated that CDK2 might also be involved in the regulation of HIF protein 
levels and transcriptional activity in endothelial cells. In contrast to CDK5, this kinase is a 
main player in cell cyle control, especially in G1/S phase transition (105, 106). However, also 
a connection to HIF was already reported by Hubbi et al. (107). In line with the findings of this 
study, they showed that CDK2 enhances HIF-1α transactivation function in the cancer cell 
lines HeLa and Hep3B. However, they revealed a decrease in HIF-1α protein levels 
promoted by CDK2, explaining this contradictory mechanism based on two assumptions: 
cancer cells promote HIF-1α degradation because the transcription factor induces cell cycle 
arrest during hypoxia (108) and cells try to compensate this by an increased HIF-1 target 
gene transcription (107). However, there are several reports underlining that this might be 
quite different in endothelial cells, because cells need to proliferate to ensure a sufficient 
blood supply of the tumor. Pro-proliferative mechanisms like the release of VEGF (109, 110) 
and insulin-like growth factor (111) are up-regulated in endothelial cells and anti-proliferative 
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substances like prostacyclin (112) and heparin sulphates (113, 114) have been 
demonstrated to be reduced under hypoxia. Since CDK inhibitors developed so far target at 
least both kinases, CDK2 and CDK5, due to their low specifity, the effect on HIF by 
pharmacological CDK inhibition might even be enhanced. 
 
4.6 CDK5 inhibitors as therapeutic options in HCC therapy 
Concerning cancer therapy, roscovitine (Seliciclib, CYC202), an orally available CDK 
inhibitor, is already undergoing clinical phase IIb trials, showing an increased overall survival 
for patients with non-small cell lung cancer (Cyclacel Press Release December 21, 2010). 
However, like most kinase inhibitors, roscovitine targets the ATP binding site of kinases, 
therefore being not very specific. A new approach would be to address CDK5 activators. For 
neurons Kesavapany et al. already demonstrated the positive effect of the CDK5 inhibitory 
peptide CIP on neuronal survival. CIP results from a further truncation of P35 (aa 54-279), 
which selectively targets P25/CDK5 interaction and thus prevents CDK5 hyperactivation. A 
deregulation of CDK5 by interaction with P25 and the associated abnormal phosphorylation 
of cytoskeletal proteins, is one of the hallmarks of many neurodegenerative diseases (115). 
In brain it has already been demonstrated, that in vitro endothelial cell angiogenesis is 
increased by shifting the balance between P35/CDK5 and P25/CDK5 signaling towards P35 
(116). However, it is not clear so far, what role CDK5 deregulation plays during angiogenesis 
outside the brain and the role of P25/P35 as well as other putative activators of CDK5 in the 
endothelium are still to be identified. 
Since sorafenib is the only available oral systemic treatment for advanced stage HCC 
patients so far (9), new therapeutic agents are needed. Recently, a novel oral selective 
mesenchymal-epithelial transition (MET) inhibitor, Tivantinib, has been evaluated in a 
phase II study, showing antitumor activity in HCC as monotherapy as well as in combination 
with sorafenib (117). Interestingly, Liu et al. showed that in HCC, the homeobox protein 
PROX1 promotes HIF-1α transcription and influences its stability finally inducing epithelial-
mesenchymal transition (EMT) response (118). Consequently, targeting HIFs via CDK5 
inhibitors might not only affect angiogenesis in HCC, but putatively also influences the 
formation of metastases. 
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4.7 Conclusion and future perspectives 
In summary, the observations of this study provided novel insight into the regulation of 
angiogenesis in human endothelial and liver cancer cells. There is compelling evidence that 
CDK5 is involved in hypoxic signaling by directly stabilizing HIF-1α and HIF-2α, thus 
promoting the formation of blood vessels. Together with the findings of Ehrlich et al. (Journal 
of Hepatology, in revision) who showed that CDK5 inhibition leads to a reduced HCC 
proliferation and clonogenic survival and also reveals in vivo efficacy in a HCC xenograft 
mouse model, the importance of CDK5 as a new therapeutic target is demonstrated.  
This underlines the potential of CDK5 inhibitors as anti-cancer drugs for HCC treatment. The 
combination with other anti-angiogenic agents might even improve their efficiency and 
therefore clinical outcome for patients (82). Since HIF-1α activity is not only associated with 
cancer development but also leads to the pathogenesis of several other diseases such as 
retinopathy, pulmonary arterial hypertension as well as traumatic shock and obstructive sleep 
apnea (119), CDK5 might be of broad interest as a pharmacologically accessible therapeutic 
target with a surprising mode of action. 
 58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                          SUMMARY 
 
5 SUMMARY 
59 
5. SUMMARY 
 
Recently, the cyclin-dependent kinase 5 (CDK5), a serine/threonine kinase, has been 
identified to have a role in the regulation of angiogenesis. To test the impact of this finding on 
tumor biology, the involvement of CDK5 in angiogenesis of liver cancer was investigated in 
this study, since hepatocellular carcinoma (HCC) is one of the most vascularized solid 
tumors. Pharmacological or genetic inhibition of CDK5 in endothelial or HCC cells led to a 
reduction of HIF-1α in vitro and in vivo. Furthermore, the CDK5 inhibitor roscovitine 
significantly reduced the HIF-2α protein level in vitro. Consequently, transcription of HIF 
target genes (VEGFA, VEGFR1, EphrinA1) was decreased. Mass spectrometry revealed that 
CDK5 directly phosphorylated HIF-1α at serine 687, resulting in a stabilization of the 
transcription factor. Mutation studies confirmed the functional relevance of this 
phosphorylation site for HIF-1α stability. As in vivo proof, vascular density was decreased in 
different kinds of murine HCC models by pharmacological CDK5 inhibition. Thus, HIF was 
identified as a new substrate of CDK5 in endothelial and liver cancer cells. 
 
  
Figure 24:  CDK5 stabilizes HIF, promoting angiogenesis in HCC. 
 
Concluding, this study underlines the potential of CDK5 inhibitors as anti-angiogenic cancer 
therapeutics. Besides HCC, where high HIF levels correlate with poor prognosis, the 
pathogenesis of other diseases like retinopathy or pulmonary arterial hypertension is also 
caused by a high HIF activity. Therefore, targeting CDK5 might be of considerable general 
interest as a novel therapeutic option to address HIF-1α related diseases. 
 
CDK5
HIF-1α
stabilization
P   ser687
HIF-1β
transcription of
angiogenic factors
tumor
vascularization
Hypoxia
HIF-2α
 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              REFERENCES
6 REFERENCES 
61 
6. REFERENCES 
1. Giuliano S, and Pages G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie. 
2013;95(6):1110-9. 
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nature reviews Drug 
discovery. 2007;6(4):273-86. 
3. Bergers G, and Hanahan D. Modes of resistance to anti-angiogenic therapy. Nature reviews 
Cancer. 2008;8(8):592-603. 
4. Yue PY, Mak NK, Cheng YK, Leung KW, Ng TB, Fan DT, Yeung HW, and Wong RN. 
Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and 
steroid-like activities of ginsenosides. Chinese medicine. 2007;2(6. 
5. Folkman J, and Shing Y. Angiogenesis. The Journal of biological chemistry. 
1992;267(16):10931-4. 
6. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-4. 
7. Folkman J, and Klagsbrun M. Angiogenic factors. Science. 1987;235(4787):442-7. 
8. Chung AS, Lee J, and Ferrara N. Targeting the tumour vasculature: insights from physiological 
angiogenesis. Nature reviews Cancer. 2010;10(7):505-14. 
9. Wrzesinski SH, Taddei TH, and Strazzabosco M. Systemic therapy in hepatocellular 
carcinoma. Clinics in liver disease. 2011;15(2):423-41, vii-x. 
10. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, and Kerbel RS. Multiple circulating 
proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with 
antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of 
America. 2007;104(43):17069-74. 
11. Lu KV, and Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in 
glioblastoma. CNS oncology. 2013;2(1):49-65. 
12. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM. Estimates of worldwide 
burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal 
international du cancer. 2010;127(12):2893-917. 
13. Parkin DM, Bray F, Ferlay J, and Pisani P. Estimating the world cancer burden: Globocan 2000. 
International journal of cancer Journal international du cancer. 2001;94(2):153-6. 
14. El-Serag HB, Davila JA, Petersen NJ, and McGlynn KA. The continuing increase in the 
incidence of hepatocellular carcinoma in the United States: an update. Annals of internal 
medicine. 2003;139(10):817-23. 
15. Thomas MB, and Zhu AX. Hepatocellular carcinoma: the need for progress. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2005;23(13):2892-9. 
16. Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, and Wong J. Improving survival results after 
resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. 
Annals of surgery. 2001;234(1):63-70. 
17. Li S, Yao D, Wang L, Wu W, Qiu L, Yao M, Yao N, Zhang H, Yu D, and Ni Q. Expression 
characteristics of hypoxia-inducible factor-1alpha and its clinical values in diagnosis and 
prognosis of hepatocellular carcinoma. Hepatitis monthly. 2011;11(10):821-8. 
18. Miura H, Miyazaki T, Kuroda M, Oka T, Machinami R, Kodama T, Shibuya M, Makuuchi M, 
Yazaki Y, and Ohnishi S. Increased expression of vascular endothelial growth factor in human 
hepatocellular carcinoma. Journal of hepatology. 1997;27(5):854-61. 
19. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, and Fan ST. Prognostic significance of serum vascular 
endothelial growth factor and endostatin in patients with hepatocellular carcinoma. The 
British journal of surgery. 2004;91(10):1354-60. 
20. El-Assal ON, Yamanoi A, Ono T, Kohno H, and Nagasue N. The clinicopathological significance 
of heparanase and basic fibroblast growth factor expressions in hepatocellular carcinoma. 
Clinical cancer research : an official journal of the American Association for Cancer Research. 
2001;7(5):1299-305. 
6 REFERENCES 
62 
 
21. Poon RT, Ng IO, Lau C, Yu WC, Fan ST, and Wong J. Correlation of serum basic fibroblast 
growth factor levels with clinicopathologic features and postoperative recurrence in 
hepatocellular carcinoma. American journal of surgery. 2001;182(3):298-304. 
22. Pang RW, and Poon RT. From molecular biology to targeted therapies for hepatocellular 
carcinoma: the future is now. Oncology. 2007;72 Suppl 1(30-44. 
23. Ribatti D, Vacca A, Nico B, Sansonno D, and Dammacco F. Angiogenesis and anti-angiogenesis 
in hepatocellular carcinoma. Cancer treatment reviews. 2006;32(6):437-44. 
24. Lew J, Beaudette K, Litwin CM, and Wang JH. Purification and characterization of a novel 
proline-directed protein kinase from bovine brain. The Journal of biological chemistry. 
1992;267(19):13383-90. 
25. Liebl J, Furst R, Vollmar AM, and Zahler S. Twice switched at birth: cell cycle-independent 
roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells. Cellular 
signalling. 2011;23(11):1698-707. 
26. Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, Gertler FB, Vidal M, Van 
Etten RA, and Tsai LH. Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine 
phosphorylation, kinase upregulation, and neurite outgrowth. Neuron. 2000;26(3):633-46. 
27. Sasaki Y, Cheng C, Uchida Y, Nakajima O, Ohshima T, Yagi T, Taniguchi M, Nakayama T, 
Kishida R, Kudo Y, et al. Fyn and Cdk5 mediate semaphorin-3A signaling, which is involved in 
regulation of dendrite orientation in cerebral cortex. Neuron. 2002;35(5):907-20. 
28. Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, Goggins M, Maitra A, and Nelkin 
BD. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and 
progression through the suppression of Ras-Ral signaling. Cancer research. 2010;70(11):4460-
9. 
29. Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, Naizhen X, and 
Linnoila RI. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells 
through Cdk5/p35 pathway. Molecular biology of the cell. 2012;23(15):2856-66. 
30. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, Meyer D, Guo A, Gundara J, 
Mettlach G, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer cell. 
2013;24(4):499-511. 
31. Liebl J, Weitensteiner SB, Vereb G, Takacs L, Furst R, Vollmar AM, and Zahler S. Cyclin-
dependent kinase 5 regulates endothelial cell migration and angiogenesis. The Journal of 
biological chemistry. 2010;285(46):35932-43. 
32. Sharma MR, Tuszynski GP, and Sharma MC. Angiostatin-induced inhibition of endothelial cell 
proliferation/apoptosis is associated with the down-regulation of cell cycle regulatory protein 
cdk5. Journal of cellular biochemistry. 2004;91(2):398-409. 
33. Xie W, Wang H, He Y, Li D, Gong L, and Zhang Y. CDK5 and its activator P35 in normal 
pituitary and in pituitary adenomas: relationship to VEGF expression. International journal of 
biological sciences. 2014;10(2):192-9. 
34. Cruz JC, Kim D, Moy LY, Dobbin MM, Sun X, Bronson RT, and Tsai LH. p25/cyclin-dependent 
kinase 5 induces production and intraneuronal accumulation of amyloid beta in vivo. The 
Journal of neuroscience : the official journal of the Society for Neuroscience. 
2006;26(41):10536-41. 
35. Cruz JC, and Tsai LH. Cdk5 deregulation in the pathogenesis of Alzheimer's disease. Trends in 
molecular medicine. 2004;10(9):452-8. 
36. Sadleir KR, and Vassar R. Cdk5 protein inhibition and Abeta42 increase BACE1 protein level in 
primary neurons by a post-transcriptional mechanism: implications of CDK5 as a therapeutic 
target for Alzheimer disease. The Journal of biological chemistry. 2012;287(10):7224-35. 
37. Wong AS, Lee RH, Cheung AY, Yeung PK, Chung SK, Cheung ZH, and Ip NY. Cdk5-mediated 
phosphorylation of endophilin B1 is required for induced autophagy in models of Parkinson's 
disease. Nature cell biology. 2011;13(5):568-79. 
38. Anne SL, Saudou F, and Humbert S. Phosphorylation of huntingtin by cyclin-dependent kinase 
5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in 
6 REFERENCES 
63 
 
neurons. The Journal of neuroscience : the official journal of the Society for Neuroscience. 
2007;27(27):7318-28. 
39. Menn B, Bach S, Blevins TL, Campbell M, Meijer L, and Timsit S. Delayed treatment with 
systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase 
in animal stroke models. PloS one. 2010;5(8):e12117. 
40. Pareek TK, and Kulkarni AB. Cdk5: a new player in pain signaling. Cell cycle. 2006;5(6):585-8. 
41. Utreras E, Futatsugi A, Rudrabhatla P, Keller J, Iadarola MJ, Pant HC, and Kulkarni AB. Tumor 
necrosis factor-alpha regulates cyclin-dependent kinase 5 activity during pain signaling 
through transcriptional activation of p35. The Journal of biological chemistry. 
2009;284(4):2275-84. 
42. Wei FY, Nagashima K, Ohshima T, Saheki Y, Lu YF, Matsushita M, Yamada Y, Mikoshiba K, 
Seino Y, Matsui H, et al. Cdk5-dependent regulation of glucose-stimulated insulin secretion. 
Nature medicine. 2005;11(10):1104-8. 
43. Vesely J, Havlicek L, Strnad M, Blow JJ, Donella-Deana A, Pinna L, Letham DS, Kato J, Detivaud 
L, Leclerc S, et al. Inhibition of cyclin-dependent kinases by purine analogues. European 
journal of biochemistry / FEBS. 1994;224(2):771-86. 
44. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, and 
Moulinoux JP. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor 
of the cyclin-dependent kinases cdc2, cdk2 and cdk5. European journal of biochemistry / 
FEBS. 1997;243(1-2):527-36. 
45. Demange L, Abdellah FN, Lozach O, Ferandin Y, Gresh N, Meijer L, and Galons H. Potent 
inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular 
modelling. Bioorganic & medicinal chemistry letters. 2013;23(1):125-31. 
46. Knockaert M, Greengard P, and Meijer L. Pharmacological inhibitors of cyclin-dependent 
kinases. Trends in pharmacological sciences. 2002;23(9):417-25. 
47. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, Leost M, Damiens E, Marie 
D, Marko D, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, 
inhibits cyclin-dependent kinases. Nature cell biology. 1999;1(1):60-7. 
48. Mettey Y, Gompel M, Thomas V, Garnier M, Leost M, Ceballos-Picot I, Noble M, Endicott J, 
Vierfond JM, and Meijer L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal 
structure in complex with CDK2, enzyme selectivity, and cellular effects. Journal of medicinal 
chemistry. 2003;46(2):222-36. 
49. Zaharevitz DW, Gussio R, Leost M, Senderowicz AM, Lahusen T, Kunick C, Meijer L, and 
Sausville EA. Discovery and initial characterization of the paullones, a novel class of small-
molecule inhibitors of cyclin-dependent kinases. Cancer research. 1999;59(11):2566-9. 
50. Haider C, Grubinger M, Reznickova E, Weiss TS, Rotheneder H, Miklos W, Berger W, Jorda R, 
Zatloukal M, Gucky T, et al. Novel inhibitors of cyclin-dependent kinases combat 
hepatocellular carcinoma without inducing chemoresistance. Molecular cancer therapeutics. 
2013;12(10):1947-57. 
51. Antoniou X, Gassmann M, and Ogunshola OO. Cdk5 interacts with Hif-1alpha in neurons: a 
new hypoxic signalling mechanism? Brain research. 2011;1381(1-10. 
52. Jiang BH, Rue E, Wang GL, Roe R, and Semenza GL. Dimerization, DNA binding, and 
transactivation properties of hypoxia-inducible factor 1. The Journal of biological chemistry. 
1996;271(30):17771-8. 
53. Ke Q, and Costa M. Hypoxia-inducible factor-1 (HIF-1). Molecular pharmacology. 
2006;70(5):1469-80. 
54. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, and Gassmann M. Induction of HIF-
1alpha in response to hypoxia is instantaneous. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology. 2001;15(7):1312-4. 
55. Wang GL, Jiang BH, Rue EA, and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-
helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National 
Academy of Sciences of the United States of America. 1995;92(12):5510-4. 
6 REFERENCES 
64 
 
56. Wang GL, and Semenza GL. Purification and characterization of hypoxia-inducible factor 1. 
The Journal of biological chemistry. 1995;270(3):1230-7. 
57. Luo D, Wang Z, Wu J, Jiang C, and Wu J. The role of hypoxia inducible factor-1 in 
hepatocellular carcinoma. BioMed research international. 2014;2014(409272. 
58. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, and Ratcliffe PJ. Activation of hypoxia-inducible 
factor-1; definition of regulatory domains within the alpha subunit. The Journal of biological 
chemistry. 1997;272(17):11205-14. 
59. Ema M, Hirota K, Mimura J, Abe H, Yodoi J, Sogawa K, Poellinger L, and Fujii-Kuriyama Y. 
Molecular mechanisms of transcription activation by HLF and HIF1alpha in response to 
hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. The EMBO 
journal. 1999;18(7):1905-14. 
60. Kallio PJ, Okamoto K, O'Brien S, Carrero P, Makino Y, Tanaka H, and Poellinger L. Signal 
transduction in hypoxic cells: inducible nuclear translocation and recruitment of the 
CBP/p300 coactivator by the hypoxia-inducible factor-1alpha. The EMBO journal. 
1998;17(22):6573-86. 
61. Brahimi-Horn C, Mazure N, and Pouyssegur J. Signalling via the hypoxia-inducible factor-
1alpha requires multiple posttranslational modifications. Cellular signalling. 2005;17(1):1-9. 
62. Xu D, Yao Y, Lu L, Costa M, and Dai W. Plk3 functions as an essential component of the 
hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha. The Journal of 
biological chemistry. 2010;285(50):38944-50. 
63. Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW, and Li CY. 
Regulation of HIF-1alpha stability through S-nitrosylation. Molecular cell. 2007;26(1):63-74. 
64. Jiang BH, Zheng JZ, Leung SW, Roe R, and Semenza GL. Transactivation and inhibitory 
domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen 
tension. The Journal of biological chemistry. 1997;272(31):19253-60. 
65. Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology. 
2004;19(176-82. 
66. Ema M, Taya S, Yokotani N, Sogawa K, Matsuda Y, and Fujii-Kuriyama Y. A novel bHLH-PAS 
factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF 
expression and is potentially involved in lung and vascular development. Proceedings of the 
National Academy of Sciences of the United States of America. 1997;94(9):4273-8. 
67. Tian H, Hammer RE, Matsumoto AM, Russell DW, and McKnight SL. The hypoxia-responsive 
transcription factor EPAS1 is essential for catecholamine homeostasis and protection against 
heart failure during embryonic development. Genes & development. 1998;12(21):3320-4. 
68. Tian H, McKnight SL, and Russell DW. Endothelial PAS domain protein 1 (EPAS1), a 
transcription factor selectively expressed in endothelial cells. Genes & development. 
1997;11(1):72-82. 
69. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota 
S, Bechmann I, Frei UA, Pugh CW, et al. Widespread hypoxia-inducible expression of HIF-
2alpha in distinct cell populations of different organs. FASEB journal : official publication of 
the Federation of American Societies for Experimental Biology. 2003;17(2):271-3. 
70. Heikkila M, Pasanen A, Kivirikko KI, and Myllyharju J. Roles of the human hypoxia-inducible 
factor (HIF)-3alpha variants in the hypoxia response. Cellular and molecular life sciences : 
CMLS. 2011;68(23):3885-901. 
71. Tanaka T, Wiesener M, Bernhardt W, Eckardt KU, and Warnecke C. The human HIF (hypoxia-
inducible factor)-3alpha gene is a HIF-1 target gene and may modulate hypoxic gene 
induction. The Biochemical journal. 2009;424(1):143-51. 
72. Maynard MA, Evans AJ, Shi W, Kim WY, Liu FF, and Ohh M. Dominant-negative HIF-3 alpha 4 
suppresses VHL-null renal cell carcinoma progression. Cell cycle. 2007;6(22):2810-6. 
73. Rankin EB, and Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell death 
and differentiation. 2008;15(4):678-85. 
6 REFERENCES 
65 
 
74. Faller DV. Endothelial cell responses to hypoxic stress. Clinical and experimental 
pharmacology & physiology. 1999;26(1):74-84. 
75. Fischer C, Mazzone M, Jonckx B, and Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug 
targets for anti-angiogenic therapy? Nature reviews Cancer. 2008;8(12):942-56. 
76. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L, and Isner JM. 
Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. The 
Journal of biological chemistry. 1995;270(52):31189-95. 
77. Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF, and Jing S. Prognostic significance of HIF-
2alpha/EPAS1 expression in hepatocellular carcinoma. World journal of gastroenterology : 
WJG. 2007;13(23):3176-82. 
78. Xie H, Song J, Liu K, Ji H, Shen H, Hu S, Yang G, Du Y, Zou X, Jin H, et al. The expression of 
hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: 
correlation with patients' prognosis and hepatitis B virus X protein. Digestive diseases and 
sciences. 2008;53(12):3225-33. 
79. Dimova EY, Michiels C, and Kietzmann T. Kinases as upstream regulators of the HIF system: 
their emerging potential as anti-cancer drug targets. Current pharmaceutical design. 
2009;15(33):3867-77. 
80. Xia Y, Choi HK, and Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. 
European journal of medicinal chemistry. 2012;49(24-40. 
81. Sadri N, and Zhang PJ. Hypoxia-inducible factors: mediators of cancer progression; prognostic 
and therapeutic targets in soft tissue sarcomas. Cancers. 2013;5(2):320-33. 
82. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for 
cancer therapy. Trends in pharmacological sciences. 2012;33(4):207-14. 
83. Menrad H, Werno C, Schmid T, Copanaki E, Deller T, Dehne N, and Brune B. Roles of hypoxia-
inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor 
spheroids. Hepatology. 2010;51(6):2183-92. 
84. Roxburgh P, and Evans TR. Systemic therapy of hepatocellular carcinoma: are we making 
progress? Advances in therapy. 2008;25(11):1089-104. 
85. Zatloukal M, Jorda R, Gucky T, Reznickova E, Voller J, Pospisil T, Malinkova V, Adamcova H, 
Krystof V, and Strnad M. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted 
purines targeting multiple cyclin-dependent kinases. European journal of medicinal 
chemistry. 2013;61(61-72. 
86. van den Heuvel S, and Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle 
control. Science. 1993;262(5142):2050-4. 
87. Baker SJ, Markowitz S, Fearon ER, Willson JK, and Vogelstein B. Suppression of human 
colorectal carcinoma cell growth by wild-type p53. Science. 1990;249(4971):912-5. 
88. Kondo K, Klco J, Nakamura E, Lechpammer M, and Kaelin WG, Jr. Inhibition of HIF is 
necessary for tumor suppression by the von Hippel-Lindau protein. Cancer cell. 
2002;1(3):237-46. 
89. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic 
acids research. 2001;29(9):e45. 
90. Tardio JC. CD34-reactive tumors of the skin. An updated review of an ever-growing list of 
lesions. Journal of cutaneous pathology. 2009;36(1):89-102. 
91. Liao D, and Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer metastasis 
reviews. 2007;26(2):281-90. 
92. Iida H, Honda M, Kawai HF, Yamashita T, Shirota Y, Wang BC, Miao H, and Kaneko S. Ephrin-
A1 expression contributes to the malignant characteristics of {alpha}-fetoprotein producing 
hepatocellular carcinoma. Gut. 2005;54(6):843-51. 
93. Manohar SM, Padgaonkar AA, Jalota-Badhwar A, Rao SV, and Joshi KS. Cyclin-dependent 
kinase inhibitor, P276-00, inhibits HIF-1alpha and induces G2/M arrest under hypoxia in 
prostate cancer cells. Prostate cancer and prostatic diseases. 2012;15(1):15-27. 
6 REFERENCES 
66 
 
94. Ribatti D, Vacca A, and Dammacco F. The role of the vascular phase in solid tumor growth: a 
historical review. Neoplasia. 1999;1(4):293-302. 
95. Zhu AX, Duda DG, Sahani DV, and Jain RK. HCC and angiogenesis: possible targets and future 
directions. Nature reviews Clinical oncology. 2011;8(5):292-301. 
96. Pang R, and Poon RT. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. 
Cancer letters. 2006;242(2):151-67. 
97. Zeng W, Gouw AS, van den Heuvel MC, Zwiers PJ, Zondervan PE, Poppema S, Zhang N, 
Platteel I, de Jong KP, and Molema G. The angiogenic makeup of human hepatocellular 
carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting 
neovascularization. Hepatology. 2008;48(5):1517-27. 
98. Wu XZ, Xie GR, and Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target 
for hepatocellular carcinoma. Journal of gastroenterology and hepatology. 2007;22(8):1178-
82. 
99. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, and Kim KW. 
Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 
2002;111(5):709-20. 
100. Wang GL, Jiang BH, and Semenza GL. Effect of protein kinase and phosphatase inhibitors on 
expression of hypoxia-inducible factor 1. Biochemical and biophysical research 
communications. 1995;216(2):669-75. 
101. Warfel NA, Dolloff NG, Dicker DT, Malysz J, and El-Deiry WS. CDK1 stabilizes HIF-1alpha via 
direct phosphorylation of Ser668 to promote tumor growth. Cell cycle. 2013;12(23):3689-
701. 
102. Cam H, Easton JB, High A, and Houghton PJ. mTORC1 signaling under hypoxic conditions is 
controlled by ATM-dependent phosphorylation of HIF-1alpha. Molecular cell. 
2010;40(4):509-20. 
103. Shetty KT, Link WT, and Pant HC. cdc2-like kinase from rat spinal cord specifically 
phosphorylates KSPXK motifs in neurofilament proteins: isolation and characterization. 
Proceedings of the National Academy of Sciences of the United States of America. 
1993;90(14):6844-8. 
104. Grant P, Sharma P, and Pant HC. Cyclin-dependent protein kinase 5 (Cdk5) and the regulation 
of neurofilament metabolism. European journal of biochemistry / FEBS. 2001;268(6):1534-46. 
105. Saha P, Chen J, Thome KC, Lawlis SJ, Hou ZH, Hendricks M, Parvin JD, and Dutta A. Human 
CDC6/Cdc18 associates with Orc1 and cyclin-cdk and is selectively eliminated from the 
nucleus at the onset of S phase. Molecular and cellular biology. 1998;18(5):2758-67. 
106. Lei M, Kawasaki Y, Young MR, Kihara M, Sugino A, and Tye BK. Mcm2 is a target of regulation 
by Cdc7-Dbf4 during the initiation of DNA synthesis. Genes & development. 
1997;11(24):3365-74. 
107. Hubbi ME, Gilkes DM, Hu H, Kshitiz, Ahmed I, and Semenza GL. Cyclin-dependent kinases 
regulate lysosomal degradation of hypoxia-inducible factor 1alpha to promote cell-cycle 
progression. Proceedings of the National Academy of Sciences of the United States of 
America. 2014;111(32):E3325-34. 
108. Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, and Johnson RS. Hypoxia-inducible factor 
1alpha is essential for cell cycle arrest during hypoxia. Molecular and cellular biology. 
2003;23(1):359-69. 
109. Shweiki D, Itin A, Soffer D, and Keshet E. Vascular endothelial growth factor induced by 
hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992;359(6398):843-5. 
110. Shweiki D, Neeman M, Itin A, and Keshet E. Induction of vascular endothelial growth factor 
expression by hypoxia and by glucose deficiency in multicell spheroids: implications for 
tumor angiogenesis. Proceedings of the National Academy of Sciences of the United States of 
America. 1995;92(3):768-72. 
6 REFERENCES 
67 
 
111. Perkett EA, Badesch DB, Roessler MK, Stenmark KR, and Meyrick B. Insulin-like growth factor 
I and pulmonary hypertension induced by continuous air embolization in sheep. American 
journal of respiratory cell and molecular biology. 1992;6(1):82-7. 
112. Assender JW, Southgate KM, Hallett MB, and Newby AC. Inhibition of proliferation, but not 
of Ca2+ mobilization, by cyclic AMP and GMP in rabbit aortic smooth-muscle cells. The 
Biochemical journal. 1992;288 ( Pt 2)(527-32. 
113. Benitz WE, Kelley RT, Anderson CM, Lorant DE, and Bernfield M. Endothelial heparan sulfate 
proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. American journal of 
respiratory cell and molecular biology. 1990;2(1):13-24. 
114. Humphries DE, Lee SL, Fanburg BL, and Silbert JE. Effects of hypoxia and hyperoxia on 
proteoglycan production by bovine pulmonary artery endothelial cells. Journal of cellular 
physiology. 1986;126(2):249-53. 
115. Kesavapany S, Zheng YL, Amin N, and Pant HC. Peptides derived from Cdk5 activator p35, 
specifically inhibit deregulated activity of Cdk5. Biotechnology journal. 2007;2(8):978-87. 
116. Bosutti A, Qi J, Pennucci R, Bolton D, Matou S, Ali K, Tsai LH, Krupinski J, Petcu EB, Montaner 
J, et al. Targeting p35/Cdk5 signalling via CIP-peptide promotes angiogenesis in hypoxia. PloS 
one. 2013;8(9):e75538. 
117. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, Van Vlierberghe H, 
Trojan J, Kolligs FT, Weiss A, et al. Tivantinib for second-line treatment of advanced 
hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. The Lancet 
Oncology. 2013;14(1):55-63. 
118. Liu Y, Zhang JB, Qin Y, Wang W, Wei L, Teng Y, Guo L, Zhang B, Lin Z, Liu J, et al. PROX1 
promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible 
factor 1alpha expression and protein stability. Hepatology. 2013;58(2):692-705. 
119. Semenza GL. Hypoxia-inducible factors in physiology and medicine. Cell. 2012;148(3):399-
408. 
 
 68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         APPENDIX 
 
7 APPENDIX 
69 
7. APPENDIX 
 
7.1 Supplementary data 
7.1.1 Mass spectra 
Mass spectrometry analysis of CDK5 phosphorylation sites on HIF-1α was performed by Dr. 
T. Fröhlich from the Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, 
University of Munich. MS/MS spectrums and fragmentation tables of in vitro and in vivo 
analyses of HIF-1α are shown below. 
 
Figure 25: MS/MS spectrum and fragmentation table of peptide 
683SHPRSPNVLSVALSQR698 of HIF-1α.  
The phosphorylated serines within the peptide sequence are underlined and marked as bold. Detected 
b ions are highlighted in red and y ions are highlighted in blue. Further signals which could be 
assigned to other fragment types are highlighted in green.  
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Figure 26: MS/MS spectrum and fragmentation table of peptide 
683SHPRSPNVLSVALSQR698 of HIF-1α.  
The phosphorylated serine within the peptide sequence is underlined and marked as bold. Detected b 
ions are highlighted in red and y ions are highlighted in blue. Further signals which could be assigned 
to other types of fragments are highlighted in green.  
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7.1.2 Sequence analyses of S687A and S687E mutants 
S687A: 
 
CLUSTAL 2.1 multiple sequence alignment 
 
 
WT              TCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGA 60 
XL1A1           -----------------------------------------------------AAGCAGA 7 
                                                                     ******* 
 
WT              GCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCAC 120 
XL1A1           GCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCAC 67 
                ************************************************************ 
 
WT              TATAGGGAGACCCAAGCTTACCATGGCCTACCCNTACGACGTGCCCGACTACGCCTCCCT 180 
XL1A1           TATAGGGAGACCCAAGCTTACCATGGCCTACCCCTACGACGTGCCCGACTACGCCTCCCT 127 
                ********************************* ************************** 
 
WT              CGGATCCGCCACCATGGAGGGCGCCGGCGGCGCGAACGACAAGAAAAAGATAAGTTCTGA 240 
XL1A1           CGGATCCGCCACCATGGAGGGCGCCGGCGGCGCGAACGACAAGAAAAAGATAAGTTCTGA 187 
                ************************************************************ 
 
WT              ACGTCGAAAAGAAAAGTCTCGAGATGCAGCCAGATCTCGGCGAAGTAAAGAATCTGAAGT 300 
XL1A1           ACGTCGAAAAGAAAAGTCTCGAGATGCAGCCAGATCTCGGCGAAGTAAAGAATCTGAAGT 247 
                ************************************************************ 
 
WT              TTTTTATGAGCTTGCTCATCAGTTGCCACTTCCACATAATGTGAGTTCGCATCTTGATAA 360 
XL1A1           TTTTTATGAGCTTGCTCATCAGTTGCCACTTCCACATAATGTGAGTTCGCATCTTGATAA 307 
                ************************************************************ 
 
WT              GGCCTCTGTGATGAGGCTTACCATCAGCTATTTGCGTGTGAGGAAACTTCTGGATGCTGG 420 
XL1A1           GGCCTCTGTGATGAGGCTTACCATCAGCTATTTGCGTGTGAGGAAACTTCTGGATGCTGG 367 
                ************************************************************ 
 
WT              TGATTTGGATATTGAAGATGACATGAAAGCACAGATGAATTGCTTTTATTTGAAAGCCTT 480 
XL1A1           TGATTTGGATATTGAAGATGACATGAAAGCACAGATGAATTGCTTTTATTTGAAAGCCTT 427 
                ************************************************************ 
 
WT              GGATGGTTTTGTTATGGTTCTCACAGATGATGGTGACATGATTTACATTTCTGATAATGT 540 
XL1A1           GGATGGTTTTGTTATGGTTCTCACAGATGATGGTGACATGATTTACATTTCTGATAATGT 487 
                ************************************************************ 
 
WT              GAACAAATACATGGGATTAACTCAGTTTGAACTAACTGGACACAGTGTGTTTGATTTTAC 600 
XL1A1           GAACAAATACATGGGATTAACTCAGTTTGAACTAACTGGACACAGTGTGTTTGATTTTAC 547 
                ************************************************************ 
 
WT              TCATCCATGTGACCATGAGGAAATGAGAGAAATGCTTACACACAGAAATGGCCTTGTGAA 660 
XL1A1           TCATCCATGTGACCATGAGGAAATGAGAGAAATGCTTACACACAGAAATGGCCTTGTGAA 607 
                ************************************************************ 
 
WT              AAAGGGTAAAGAACAAAACACACAGCGAAGCTTTTTTCTCAGAATGAAGTGTACCCTAAC 720 
XL1A1           AAAGGGTAAAGAACAAAACACACAGCGAAGCTTTTTTCTCAGAATGAAGTGTACCCTAAC 667 
                ************************************************************ 
 
WT              TAGCCGAGGAAGAACTATGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACAGG 780 
XL1A1           TAGCCGAGGAAGAACTATGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACAGG 727 
                ************************************************************ 
 
WT              CCACATTCACGTATATGATACCAACAGTAACCAACCTCAGTGTGGGTATAAGAAACCACC 840 
XL1A1           CCACATTCACGTATATGATACCAACAGTAACCAACCTCAGTGTGGGTATAAGAAACCACC 787 
                ************************************************************ 
 
WT              TATGACCTGCTTGGTGCTGATTTGTGAACCCATTCCTCACCCATCAAATATTGAAATTCC 900 
XL1A1           TATGACCTGCTTGGTGCTGATTTGTGAACCCATTCCTCACCCATCAAATATTGAAATTCC 847 
                ************************************************************ 
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WT              TTTAGATAGCAAGACTTTCCTCAGTCGACACAGCCTGGATATGAAATTTTCTTATTGTGA 960 
XL1A1           TTTAGATAGCAAGACTTTCCTCAGTCGACACAGCCTGGATATGAAATTTTCTTATTGTGA 907 
                ************************************************************ 
 
WT              TGAAAGAATTACCGAATTGATGGGATATGAGCCAGAAGAACTTTTAGGCCGCTCAATTTA 1020 
XL1A1           TGAAAGAATTACCGAATTGATGGGATATGAGCCAGAAGAACTTTTAGGCCGCTCAATTTA 967 
                ************************************************************ 
 
WT              TGAATATTATCATGCTTTGGACTCTGATCATCTGACCAAAACTCATCATGATATGTTTAC 1080 
XL1A1           TGAATATTATCATGCTTTGGACTCTGATCATCTGACCAAAACTCATCATGATATGTTTAC 1027 
                ************************************************************ 
 
WT              TAAAGGACAAGTCACCACAGGACAGTACAGGATGCTTGCCAAAAGAGGTGGATATGTCTG 1140 
XL1A1           TAAAGGACAAGTCACCACAGGACAGTACAGGATGCTTGCCAAAAGAGGTGGATATGTCTG 1087 
                ************************************************************ 
 
WT              GGTTGAAACTCAAGCAACTGTCATATATAACACCAAGAATTCTCAACCACAGTGCATTGT 1200 
XL1A1           GGTTGAAACTCAAGCAACTGTCATATATAACACCAAGAATTCTCAACCACAGTGCATTGT 1147 
                ************************************************************ 
 
WT              ATGTGTGAATTACGTTGTGAGTGGTATTATTCAGCACGACTTGATTTTCTCCCTTCAACA 1260 
XL1A1           ATGTGTGAATTACGTTGTGAGTGGTATTATTCAGCACGACTTGATTTTCTCCCTTCAACA 1207 
                ************************************************************ 
 
WT              AACAGAATGTGTCCTTAAACCGGTTGAATCTTCAGATATGAAAATGACTCAGCTATTCAC 1320 
XL1A1           AACAGAATGTGTCCTTAAACCGGTTGAATCTTCAGATATGAAAATGACTCAGCTATTCAC 1267 
                ************************************************************ 
 
WT              CAAAGTTGAATCAGAAGATACAAGTAGCCTCTTTGACAAACTTAAGAAGGAACCTGATGC 1380 
XL1A1           CAAAGTTGAATCAGAAGATACAAGTAGCCTCTTTGACAAACTTAAGAAGGAACCTGATGC 1327 
                ************************************************************ 
 
WT              TTTAACTTTGCTGGCCCCAGCCGCTGGAGACACAATCATATCTTTAGATTTTGGCAGCAA 1440 
XL1A1           TTTAACTTTGCTGGCCCCAGCCGCTGGAGACACAATCATATCTTTAGATTTTGGCAGCAA 1387 
                ************************************************************ 
 
WT              CGACACAGAAACTGATGACCAGCAACTTGAGGAAGTACCATTATATAATGATGTAATGCT 1500 
XL1A1           CGACACAGAAACTGATGACCAGCAACTTGAGGAAGTACCATTATATAATGATGTAATGCT 1447 
                ************************************************************ 
 
WT              CCCCTCACCCAACGAAAAATTACAGAATATAAATTTGGCAATGTCTCCATTACCCACCGC 1560 
XL1A1           CCCCTCACCCAACGAAAAATTACAGAATATAAATTTGGCAATGTCTCCATTACCCACCGC 1507 
                ************************************************************ 
 
WT              TGAAACGCCAAAGCCACTTCGAAGTAGTGCTGACCCTGCACTCAATCAAGAAGTTGCATT 1620 
XL1A1           TGAAACGCCAAAGCCACTTCGAAGTAGTGCTGACCCTGCACTCAATCAAGAAGTTGCATT 1567 
                ************************************************************ 
 
WT              AAAATTAGAACCAAATCCAGAGTCACTGGAACTTTCTTTTACCATGCCCCAGATTCAGGA 1680 
XL1A1           AAAATTAGAACCAAATCCAGAGTCACTGGAACTTTCTTTTACCATGCCCCAGATTCAGGA 1627 
                ************************************************************ 
 
WT              TCAGACACCTAGTCCTTCCGATGGAAGCACTAGACAAAGTTCACCTGAGCCTAATAGTCC 1740 
XL1A1           TCAGACACCTAGTCCTTCCGATGGAAGCACTAGACAAAGTTCACCTGAGCCTAATAGTCC 1687 
                ************************************************************ 
 
WT              CAGTGAATATTGTTTTTATGTGGATAGTGATATGGTCAATGAATTCAAGTTGGAATTGGT 1800 
XL1A1           CAGTGAATATTGTTTTTATGTGGATAGTGATATGGTCAATGAATTCAAGTTGGAATTGGT 1747 
                ************************************************************ 
 
WT              AGAAAAACTTTTTGCTGAAGACACAGAAGCAAAGAACCCATTTTCTACTCAGGACACAGA 1860 
XL1A1           AGAAAAACTTTTTGCTGAAGACACAGAAGCAAAGAACCCATTTTCTACTCAGGACACAGA 1807 
                ************************************************************ 
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WT              TTTAGACTTGGAGATGTTAGCTCCCTATATCCCAATGGATGATGACTTCCAGTTACGTTC 1920 
XL1A1           TTTAGACTTGGAGATGTTAGCTCCCTATATCCCAATGGATGATGACTTCCAGTTACGTTC 1867 
                ************************************************************ 
 
WT              CTTCGATCAGTTGTCACCATTAGAAAGCAGTTCCGCAAGCCCTGAAAGCGCAAGTCCTCA 1980 
XL1A1           CTTCGATCAGTTGTCACCATTAGAAAGCAGTTCCGCAAGCCCTGAAAGCGCAAGTCCTCA 1927 
                ************************************************************ 
 
WT              AAGCACAGTTACAGTATTCCAGCAGACTCAAATACAAGAACCTACTGCTAATGCCACCAC 2040 
XL1A1           AAGCACAGTTACAGTATTCCAGCAGACTCAAATACAAGAACCTACTGCTAATGCCACCAC 1987 
                ************************************************************ 
 
WT              TACCACTGCCACCACTGATGAATTAAAAACAGTGACAAAAGACCGTATGGAAGACATTAA 2100 
XL1A1           TACCACTGCCACCACTGATGAATTAAAAACAGTGACAAAAGACCGTATGGAAGACATTAA 2047 
                ************************************************************ 
 
WT              AATATTGATTGCATCTCCATCTCCTACCCACATACATAAAGAAACTACTAGTGCCACATC 2160 
XL1A1           AATATTGATTGCATCTCCATCTCCTACCCACATACATAAAGAAACTACTAGTGCCACATC 2107 
                ************************************************************ 
 
WT              ATCACCATATAGAGATACTCAAAGTCGGACAGCCTCACCAAACAGAGCAGGAAAAGGAGT 2220 
XL1A1           ATCACCATATAGAGATACTCAAAGTCGGACAGCCTCACCAAACAGAGCAGGAAAAGGAGT 2167 
                ************************************************************ 
 
WT              CATAGAACAGACAGAAAAATCTCATCCAAGAAGCCCTAACGTGTTATCTGTCGCTTTGAG 2280 
XL1A1           CATAGAACAGACAGAAAAATCTCATCCAAGAGCTCCTAACGTGTTATCTGTCGCTTTGAG 2227 
                *******************************.  ************************** 
 
WT              TCAAAGAACTACAGTTCCTGAGGAAGAACTAAATCCAAAGATACTAGCTTTGCAGAATGC 2340 
XL1A1           TCAAAGAACTACAGTTCCTGAGGAAGAACTAAATCCAAAGATACTAGCTTTGCAGAATGC 2287 
                ************************************************************ 
 
WT              TCAGAGAAAGCGAAAAATGGAACATGATGGTTCACTTTTTCAAGCAGTAGGAATTGGAAC 2400 
XL1A1           TCAGAGAAAGCGAAAAATGGAACATGATGGTTCACTTTTTCAAGCAGTAGGAATTGGAAC 2347 
                ************************************************************ 
 
WT              ATTATTACAGCAGCCAGACGATCATGCAGCTACTACATCACTTTCTTGGAAACGTGTAAA 2460 
XL1A1           ATTATTACAGCAGCCAGACGATCATGCAGCTACTACATCACTTTCTTGGAAACGTGTAAA 2407 
                ************************************************************ 
 
WT              AGGATGCAAATCTAGTGAACAGAATGGAATGGAGCAAAAGACAATTATTTTAATACCCTC 2520 
XL1A1           AGGATGCAAATCTAGTGAACAGAATGGAATGGAGCAAAAGACAATTATTTTAATACCCTC 2467 
                ************************************************************ 
 
WT              TGATTTAGCATGTAGACTGCTGGGGCAATCAATGGATGAAAGTGGATTACCACAGCTGAC 2580 
XL1A1           TGATTTAGCATGTAGACTGCTGGGGCAATCAATGGATGAAAGTGGATTACCACAGCTGAC 2527 
                ************************************************************ 
 
WT              CAGTTATGATTGTGAAGTTAATGCTCCTATACAAGGCAGCAGAAACCTACTGCAGGGTGA 2640 
XL1A1           CAGTTATGATTGTGAAGTTAATGCTCCTATACAAGGCAGCAGAAACCTACTGCAGGGTGA 2587 
                ************************************************************ 
 
WT              AGAATTACTCAGAGCTTTGGATCAAGTTAACTGACAATTCTGCAGATATCCATCACACTG 2700 
XL1A1           AGAATTACTCAGAGCTTTGGATCAAGTTAACTGACAATTCTGCAGATATCCATCACACTG 2647 
                ************************************************************ 
 
WT              GCGGCCGCTCGAGCATGCATCTAGAGG 2727 
XL1A1           GCGGCC--------------------- 2653 
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S687E: 
 
CLUSTAL 2.1 multiple sequence alignment 
 
 
WT              TCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGA 60 
XL1E11          --------------------------------------------------------CAGA 4 
                                                                        **** 
 
WT              GCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCAC 120 
XL1E11          GCTCTCTGGCTAACTAGAGAACCCACTGCTTACTGGCTTATCGAAATTAATACGACTCAC 64 
                ************************************************************ 
 
WT              TATAGGGAGACCCAAGCTTACCATGGCCTACCCNTACGACGTGCCCGACTACGCCTCCCT 180 
XL1E11          TATAGGGAGACCCAAGCTTACCATGGCCTACCCCTACGACGTGCCCGACTACGCCTCCCT 124 
                ********************************* ************************** 
 
WT              CGGATCCGCCACCATGGAGGGCGCCGGCGGCGCGAACGACAAGAAAAAGATAAGTTCTGA 240 
XL1E11          CGGATCCGCCACCATGGAGGGCGCCGGCGGCGCGAACGACAAGAAAAAGATAAGTTCTGA 184 
                ************************************************************ 
 
WT              ACGTCGAAAAGAAAAGTCTCGAGATGCAGCCAGATCTCGGCGAAGTAAAGAATCTGAAGT 300 
XL1E11          ACGTCGAAAAGAAAAGTCTCGAGATGCAGCCAGATCTCGGCGAAGTAAAGAATCTGAAGT 244 
                ************************************************************ 
 
WT              TTTTTATGAGCTTGCTCATCAGTTGCCACTTCCACATAATGTGAGTTCGCATCTTGATAA 360 
XL1E11          TTTTTATGAGCTTGCTCATCAGTTGCCACTTCCACATAATGTGAGTTCGCATCTTGATAA 304 
                ************************************************************ 
 
WT              GGCCTCTGTGATGAGGCTTACCATCAGCTATTTGCGTGTGAGGAAACTTCTGGATGCTGG 420 
XL1E11          GGCCTCTGTGATGAGGCTTACCATCAGCTATTTGCGTGTGAGGAAACTTCTGGATGCTGG 364 
                ************************************************************ 
 
WT              TGATTTGGATATTGAAGATGACATGAAAGCACAGATGAATTGCTTTTATTTGAAAGCCTT 480 
XL1E11          TGATTTGGATATTGAAGATGACATGAAAGCACAGATGAATTGCTTTTATTTGAAAGCCTT 424 
                ************************************************************ 
 
WT              GGATGGTTTTGTTATGGTTCTCACAGATGATGGTGACATGATTTACATTTCTGATAATGT 540 
XL1E11          GGATGGTTTTGTTATGGTTCTCACAGATGATGGTGACATGATTTACATTTCTGATAATGT 484 
                ************************************************************ 
 
WT              GAACAAATACATGGGATTAACTCAGTTTGAACTAACTGGACACAGTGTGTTTGATTTTAC 600 
XL1E11          GAACAAATACATGGGATTAACTCAGTTTGAACTAACTGGACACAGTGTGTTTGATTTTAC 544 
                ************************************************************ 
 
WT              TCATCCATGTGACCATGAGGAAATGAGAGAAATGCTTACACACAGAAATGGCCTTGTGAA 660 
XL1E11          TCATCCATGTGACCATGAGGAAATGAGAGAAATGCTTACACACAGAAATGGCCTTGTGAA 604 
                ************************************************************ 
 
WT              AAAGGGTAAAGAACAAAACACACAGCGAAGCTTTTTTCTCAGAATGAAGTGTACCCTAAC 720 
XL1E11          AAAGGGTAAAGAACAAAACACACAGCGAAGCTTTTTTCTCAGAATGAAGTGTACCCTAAC 664 
                ************************************************************ 
 
WT              TAGCCGAGGAAGAACTATGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACAGG 780 
XL1E11          TAGCCGAGGAAGAACTATGAACATAAAGTCTGCAACATGGAAGGTATTGCACTGCACAGG 724 
                ************************************************************ 
 
WT              CCACATTCACGTATATGATACCAACAGTAACCAACCTCAGTGTGGGTATAAGAAACCACC 840 
XL1E11          CCACATTCACGTATATGATACCAACAGTAACCAACCTCAGTGTGGGTATAAGAAACCACC 784 
                ************************************************************ 
 
WT              TATGACCTGCTTGGTGCTGATTTGTGAACCCATTCCTCACCCATCAAATATTGAAATTCC 900 
XL1E11          TATGACCTGCTTGGTGCTGATTTGTGAACCCATTCCTCACCCATCAAATATTGAAATTCC 844 
                ************************************************************ 
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WT              TTTAGATAGCAAGACTTTCCTCAGTCGACACAGCCTGGATATGAAATTTTCTTATTGTGA 960 
XL1E11          TTTAGATAGCAAGACTTTCCTCAGTCGACACAGCCTGGATATGAAATTTTCTTATTGTGA 904 
                ************************************************************ 
 
WT              TGAAAGAATTACCGAATTGATGGGATATGAGCCAGAAGAACTTTTAGGCCGCTCAATTTA 1020 
XL1E11          TGAAAGAATTACCGAATTGATGGGATATGAGCCAGAAGAACTTTTAGGCCGCTCAATTTA 964 
                ************************************************************ 
 
WT              TGAATATTATCATGCTTTGGACTCTGATCATCTGACCAAAACTCATCATGATATGTTTAC 1080 
XL1E11          TGAATATTATCATGCTTTGGACTCTGATCATCTGACCAAAACTCATCATGATATGTTTAC 1024 
                ************************************************************ 
 
WT              TAAAGGACAAGTCACCACAGGACAGTACAGGATGCTTGCCAAAAGAGGTGGATATGTCTG 1140 
XL1E11          TAAAGGACAAGTCACCACAGGACAGTACAGGATGCTTGCCAAAAGAGGTGGATATGTCTG 1084 
                ************************************************************ 
 
WT              GGTTGAAACTCAAGCAACTGTCATATATAACACCAAGAATTCTCAACCACAGTGCATTGT 1200 
XL1E11          GGTTGAAACTCAAGCAACTGTCATATATAACACCAAGAATTCTCAACCACAGTGCATTGT 1144 
                ************************************************************ 
 
WT              ATGTGTGAATTACGTTGTGAGTGGTATTATTCAGCACGACTTGATTTTCTCCCTTCAACA 1260 
XL1E11          ATGTGTGAATTACGTTGTGAGTGGTATTATTCAGCACGACTTGATTTTCTCCCTTCAACA 1204 
                ************************************************************ 
 
WT              AACAGAATGTGTCCTTAAACCGGTTGAATCTTCAGATATGAAAATGACTCAGCTATTCAC 1320 
XL1E11          AACAGAATGTGTCCTTAAACCGGTTGAATCTTCAGATATGAAAATGACTCAGCTATTCAC 1264 
                ************************************************************ 
 
WT              CAAAGTTGAATCAGAAGATACAAGTAGCCTCTTTGACAAACTTAAGAAGGAACCTGATGC 1380 
XL1E11          CAAAGTTGAATCAGAAGATACAAGTAGCCTCTTTGACAAACTTAAGAAGGAACCTGATGC 1324 
                ************************************************************ 
 
WT              TTTAACTTTGCTGGCCCCAGCCGCTGGAGACACAATCATATCTTTAGATTTTGGCAGCAA 1440 
XL1E11          TTTAACTTTGCTGGCCCCAGCCGCTGGAGACACAATCATATCTTTAGATTTTGGCAGCAA 1384 
                ************************************************************ 
 
WT              CGACACAGAAACTGATGACCAGCAACTTGAGGAAGTACCATTATATAATGATGTAATGCT 1500 
XL1E11          CGACACAGAAACTGATGACCAGCAACTTGAGGAAGTACCATTATATAATGATGTAATGCT 1444 
                ************************************************************ 
 
WT              CCCCTCACCCAACGAAAAATTACAGAATATAAATTTGGCAATGTCTCCATTACCCACCGC 1560 
XL1E11          CCCCTCACCCAACGAAAAATTACAGAATATAAATTTGGCAATGTCTCCATTACCCACCGC 1504 
                ************************************************************ 
 
WT              TGAAACGCCAAAGCCACTTCGAAGTAGTGCTGACCCTGCACTCAATCAAGAAGTTGCATT 1620 
XL1E11          TGAAACGCCAAAGCCACTTCGAAGTAGTGCTGACCCTGCACTCAATCAAGAAGTTGCATT 1564 
                ************************************************************ 
 
WT              AAAATTAGAACCAAATCCAGAGTCACTGGAACTTTCTTTTACCATGCCCCAGATTCAGGA 1680 
XL1E11          AAAATTAGAACCAAATCCAGAGTCACTGGAACTTTCTTTTACCATGCCCCAGATTCAGGA 1624 
                ************************************************************ 
 
WT              TCAGACACCTAGTCCTTCCGATGGAAGCACTAGACAAAGTTCACCTGAGCCTAATAGTCC 1740 
XL1E11          TCAGACACCTAGTCCTTCCGATGGAAGCACTAGACAAAGTTCACCTGAGCCTAATAGTCC 1684 
                ************************************************************ 
 
WT              CAGTGAATATTGTTTTTATGTGGATAGTGATATGGTCAATGAATTCAAGTTGGAATTGGT 1800 
XL1E11          CAGTGAATATTGTTTTTATGTGGATAGTGATATGGTCAATGAATTCAAGTTGGAATTGGT 1744 
                ************************************************************ 
 
WT              AGAAAAACTTTTTGCTGAAGACACAGAAGCAAAGAACCCATTTTCTACTCAGGACACAGA 1860 
XL1E11          AGAAAAACTTTTTGCTGAAGACACAGAAGCAAAGAACCCATTTTCTACTCAGGACACAGA 1804 
                ************************************************************ 
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Figure 27: Point mutations at serine 687 to either alanine or glutamate were 
introduced in HIF-1α by site-directed mutagenesis. 
Sequence alignment of wildtype HIF-1α (wt) with the alanine (clone XL1A1) and glutamate (clone 
XL1E11) mutant of serine 687 is shown. Mutated sites are indicated in red. 
  
WT              TTTAGACTTGGAGATGTTAGCTCCCTATATCCCAATGGATGATGACTTCCAGTTACGTTC 1920 
XL1E11          TTTAGACTTGGAGATGTTAGCTCCCTATATCCCAATGGATGATGACTTCCAGTTACGTTC 1864 
                ************************************************************ 
 
WT              CTTCGATCAGTTGTCACCATTAGAAAGCAGTTCCGCAAGCCCTGAAAGCGCAAGTCCTCA 1980 
XL1E11          CTTCGATCAGTTGTCACCATTAGAAAGCAGTTCCGCAAGCCCTGAAAGCGCAAGTCCTCA 1924 
                ************************************************************ 
 
WT              AAGCACAGTTACAGTATTCCAGCAGACTCAAATACAAGAACCTACTGCTAATGCCACCAC 2040 
XL1E11          AAGCACAGTTACAGTATTCCAGCAGACTCAAATACAAGAACCTACTGCTAATGCCACCAC 1984 
                ************************************************************ 
 
WT              TACCACTGCCACCACTGATGAATTAAAAACAGTGACAAAAGACCGTATGGAAGACATTAA 2100 
XL1E11          TACCACTGCCACCACTGATGAATTAAAAACAGTGACAAAAGACCGTATGGAAGACATTAA 2044 
                ************************************************************ 
 
WT              AATATTGATTGCATCTCCATCTCCTACCCACATACATAAAGAAACTACTAGTGCCACATC 2160 
XL1E11          AATATTGATTGCATCTCCATCTCCTACCCACATACATAAAGAAACTACTAGTGCCACATC 2104 
                ************************************************************ 
 
WT              ATCACCATATAGAGATACTCAAAGTCGGACAGCCTCACCAAACAGAGCAGGAAAAGGAGT 2220 
XL1E11          ATCACCATATAGAGATACTCAAAGTCGGACAGCCTCACCAAACAGAGCAGGAAAAGGAGT 2164 
                ************************************************************ 
 
WT              CATAGAACAGACAGAAAAATCTCATCCAAGAAGCCCTAACGTGTTATCTGTCGCTTTGAG 2280 
XL1E11          CATAGAACAGACAGAAAAATCTCATCCAAGAGAGCCTAACGTGTTATCTGTCGCTTTGAG 2224 
                *******************************.. ************************** 
 
WT              TCAAAGAACTACAGTTCCTGAGGAAGAACTAAATCCAAAGATACTAGCTTTGCAGAATGC 2340 
XL1E11          TCAAAGAACTACAGTTCCTGAGGAAGAACTAAATCCAAAGATACTAGCTTTGCAGAATGC 2284 
                ************************************************************ 
 
WT              TCAGAGAAAGCGAAAAATGGAACATGATGGTTCACTTTTTCAAGCAGTAGGAATTGGAAC 2400 
XL1E11          TCAGAGAAAGCGAAAAATGGAACATGATGGTTCACTTTTTCAAGCAGTAGGAATTGGAAC 2344 
                ************************************************************ 
 
WT              ATTATTACAGCAGCCAGACGATCATGCAGCTACTACATCACTTTCTTGGAAACGTGTAAA 2460 
XL1E11          ATTATTACAGCAGCCAGACGATCATGCAGCTACTACATCACTTTCTTGGAAACGTGTAAA 2404 
                ************************************************************ 
 
WT              AGGATGCAAATCTAGTGAACAGAATGGAATGGAGCAAAAGACAATTATTTTAATACCCTC 2520 
XL1E11          AGGATGCAAATCTAGTGAACAGAATGGAATGGAGCAAAAGACAATTATTTTAATACCCTC 2464 
                ************************************************************ 
 
WT              TGATTTAGCATGTAGACTGCTGGGGCAATCAATGGATGAAAGTGGATTACCACAGCTGAC 2580 
XL1E11          TGATTTAGCATGTAGACTGCTGGGGCAATCAATGGATGAAAGTGGATTACCACAGCTGAC 2524 
                ************************************************************ 
 
WT              CAGTTATGATTGTGAAGTTAATGCTCCTATACAAGGCAGCAGAAACCTACTGCAGGGTGA 2640 
XL1E11          CAGTTATGATTGTGAAGTTAATGCTCCTATACAAGGCAGCAGAAACCTACTGCAGGGTGA 2584 
                ************************************************************ 
 
WT              AGAATTACTCAGAGCTTTGGATCAAGTTAACTGACAATTCTGCAGATATCCATCACACTG 2700 
XL1E11          AGAATTACTCAGAGCTTTGGATCAAGTTAACTGACAATTCTGCAGATATCCATCACACTG 2644 
                ************************************************************ 
 
WT              GCGGCCGCT-CGAGCATGCATCTAGAGG 2727 
XL1E11          GCGGCCGCTTCGA--------------- 2657 
                ********* ***                
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7.2 Abbreviations 
AEC 3-amino-9-ethylcarbazole 
ANOVA analysis of variance 
ATM ataxia telangiectasia mutated  
ATP adenosine 5´ tri-phosphat 
BA12 (2-[[[2-[(4-aminocyclohexyl)amino]-9-cyclopentyl-purin-6-yl]amino]methyl]-
4-chloro-phenol) 
bHLH basic-helix-loop-helix 
BP14 (N2-(4-aminocyclohexyl)-9-cyclopentyl-N6-[[6-(2-furyl)-3-
pyridyl]methyl]purine-2,6-diamine) 
BSA bovine serum albumin 
c-Abl c-Abelson 
CBP CREB-binding protein 
CD31 cluster of differentiation 31 
CDK cyclin-dependent kinase 
CREB cAMP response element-binding protein 
C-TAD C-terminal transactivation domain 
DEN diethylnitrosamine 
DFO deferoxamine 
DMEM Dulbecco´s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DTT dithiothreitol 
ECGM endothelial cell growth medium 
EDTA ethylene diamine tetraacetic acid 
EGTA ethylene glycol tetraacetic acid 
EMT epithelial-mesenchymal transition 
EPC endothelial progenitor cells 
FCS fetal calf serum 
FIH-1 factor-inhibiting-HIF-1 
HA hemagglutinin 
HCC hepatocellular carcinoma 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid  
HIF hypoxia-inducible factor 
HRP horseradish peroxidase 
HUVEC human umbilical vein endothelial cells 
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JCRB Japanese Collection of Research Bioresources 
MET mesenchymal-epithelial transition 
MMP matrix metalloproteinase 
mTOR mammalian target of rapamycin 
NES nuclear export signal 
NLS nuclear localization signal 
nt non-targeting 
N-TAD N-terminal transactivation domain 
ODDD oxygen-dependent degradation domain 
PAS PER-ARNT-SIM 
PDGF platelet-derived growth factor 
PDH prolyl hydroxylase 
PF pro-angiogenic factors 
PLGF placental growth factor 
PMSF phenylmethylsulfonyl fluoride 
PROX1 prospero homeobox 1 
Rac1 Ras-related C3 botulinum toxin substrate 1 
RT room temperature 
SCID severe combined immunodeficiency 
SDS Sodium dodecyl sulfate 
SEM standard error of mean 
shRNA short hairpin RNA 
siRNA small interfering RNA 
T/E trypsin/EDTA 
VEGF vascular endothelial growth factor 
VEGFR1 vascular endothelial growth factor receptor 1 
VHL Von Hippel-Lindau protein 
wt wild-type 
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Wolfgang Mikulits3, Angelika M. Vollmar1, Stefan Zahler1 
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Feodor-Lynen-Straße 25, 81377 Munich, Germany 
3Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center 
Vienna, Medical University of Vienna, Borschke-Gasse 8A,1090 Vienna, Austria 
In preparation 
 
 
7.3.2 Poster presentations 
 
CDK5 stabilizes HIF-1α in endothelial and liver tumor cells: a novel signaling 
mechanism important for HCC therapy 
Julia Herzog1, Sandra M. Stamm1, Johanna Liebl1, Angelika M. Vollmar1, Stefan Zahler1 
1Department of Pharmacy, Pharmaceutical Biology, University of Munich, Munich, Germany 
SPSAS – Advances in Molecular Oncology: Translating Molecular Biology into Cancer 
Treatment 2013, February 3-8, São Paulo, Brazil. 
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CDK5 regulates angiogenesis via stabilizing HIF-1α in endothelial and liver tumor 
cells: a novel signaling mechanism with potential importance for HCC therapy 
Herzog, J.1; Ehrlich, S. M.1; Liebl, J.1; Fröhlich, T.2; Mikulits, W.3; Vollmar, A.M.1; Zahler, S.1 
1Department of Pharmacy, Pharmaceutical Biology, University of Munich, Butenandtstr. 5-13, 81377 
Munich, Germany 
2Gene Center Munich, University of Munich, Feodor-Lynen-Strasse 25, 81377 Munich, Germany 
3Department of Medicine I, Division: Institute of Cancer Research, Comprehensive Cancer Center 
Vienna, Medical University of Vienna, Spitalgasse 23,1090 Vienna, Austria 
Deutsche Pharmazeutische Gesellschaft (DPhG) Tagung 2014, September 24-26th, 
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